10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2011

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 1-33094

AMERICAN CARESOURCE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE		20-0428568
(State or other jurisdiction of		(I.R.S. employer
incorporation or organization)		identification no.)
	5429 LYNDON B. JOHNSON FREEWAY
	SUITE 850
	DALLAS, TEXAS
	75240
	(Address of principal executive offices)
	(Zip code)

(972) 308-6830

(Registrant’s telephone number, including area code)

 Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common Stock, par value $.01 per share	The NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Exchange Act:

None

Indicate by checkmark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act of 1933 (the “Securities Act”). Yes o No x

Indicate by checkmark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”). Yes o No x

Indicate by checkmark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained in this form, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by checkmark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Non-accelerated filer o
Accelerated filer  o	Smaller Reporting Company x

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The aggregate market value of the voting and nonvoting Common Stock held by non-affiliates of the Registrant was $12,442,784 computed by reference to the price at which the Common Stock was last sold on The NASDAQ Capital Market on the last business day of the Registrant’s most recently completed second fiscal quarter (June 30, 2011).

The number of shares of the Registrant’s Common Stock, par value $.01 per share, outstanding as of March 5, 2012 was 17,075,620.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant's definitive proxy statement for the 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, to be filed with the Securities and Exchange Commission not later than April 30, 2011, are incorporated by reference into Part III of this Form 10-K.

AMERICAN CARESOURCE HOLDINGS, INC.

FORM 10-K

TABLE OF CONTENTS

PART I
Item 1	Business	1
Item 1A	Risk Factors	10
Item 2	Properties	15
Item 3	Legal Proceedings	16
Item 4	Mine Safety Disclosures	16
PART II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	17
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operation	18
Item 8	Financial Statements and Supplementary Data	27
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	27
Item 9A	Controls and Procedures	28
Item 9B	Other Information	28
PART III
Item 10	Directors, Executive Officers, and Corporate Governance	29
Item 11	Executive Compensation	29
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	29
Item 13	Certain Relationships and Related Transactions, and Director Independence	30
Item 14	Principal Accounting Fees and Services	30
PART IV
Item 15	Exhibits and Financial Statement Schedules	31
Index to Financial Statements
Report of Independent Registered Public Accounting Firm		F-1
Consolidated Statements of Operations		F-2
Consolidated Balance Sheets		F-3
Consolidated Statements of Stockholders’ Equity		F-4
Consolidated Statements of Cash Flows		F-5
Notes to Consolidated Financial Statements		F-6

Special Note Regarding Forward-Looking Statements

This annual report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by forward-looking words such as “may,” “will,” “expect,” “intend”, “anticipate,” “believe,” “estimate” and “continue” or similar words and discuss the Company’s plans, objectives and expectations for future operations, including its services, contain projections of the Company’s future operating results or financial condition, and discuss its expectations with respect to the growth in health care costs in the United States, the demand for ancillary benefits management services, and the Company’s competitive advantages, or contain other “forward-looking” information.

Such forward-looking statements are based on current information, assumptions and belief of management, and are not guarantees of future performance.  Substantial risks and uncertainties could cause actual results to differ materially from those indicated by such forward-looking statements, including, but not limited to, the Company’s inability to attract or maintain providers or clients or achieve its financial results, changes in national health care policy, federal or state regulation, and/or rates of reimbursement including without limitation the impact of the Patient Protection and Affordable Care Act, Health Care and Educational Affordability Reconciliation Act and medical loss ratio regulations, general economic conditions (including economic downturns and increases in unemployment), lower than anticipated demand for ancillary services, pricing, market acceptance/preference, the Company’s ability to integrate with its clients, consolidation in the industry that may affect the Company’s key clients, changes in the business decisions by significant clients, increased competition, the Company’s inability to manage growth, implementation and performance difficulties, and other risk factors detailed from time to time in the Company’s periodic filings with the Securities and Exchange Commission, including in this annual report on Form 10-K for the year ended December 31, 2011.

Do not place undue reliance on these forward-looking statements, which speak only as of the date this document was prepared.  All forward-looking statements included herein are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.  Except to the extent required by applicable securities laws and regulations, the Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.

ii

PART I

Item 1.                    Business.

Overview

American CareSource Holdings, Inc. (“ACS,” “Company,”  the “Registrant,” “we,” “us,” or “our”) is an ancillary services company that offers cost effective access to a comprehensive national network of ancillary healthcare service providers.  The Company sells its services to a number of healthcare companies including third party administrators (“TPAs”), insurance companies, self-funded organizations, preferred provider organizations ("PPOs") and various employee groups.  The Company offers payors this solution through the following:

• lowering its payors’ ancillary care costs throughout our network of high quality, cost effective providers that the Company has under contract at more favorable terms than the payors could generally obtain on their own; generally we provide our payor clients with 8-12% incremental savings on their ancillary healthcare services expenditures;

• providing payors with a comprehensive network of ancillary healthcare services providers that is tailored to each payor’s specific needs and is available to each payor’s covered persons for covered services;

• providing payors with claims management, reporting and processing and payment services;

• performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor-specific provider networks; and

• credentialing network service providers for inclusion in the payor-specific provider networks.  

The Company has assembled a network of ancillary healthcare service providers that supplement or support the care provided by hospitals and physicians and includes 30 service categories. The Company has a dedicated provider development function comprised of nine full-time employees, whose primary responsibility is to contract with providers and strategically grow our network of ancillary service providers.

We secure contracts with ancillary service providers by offering them the following:

• inclusion in a nationwide network that provides exposure to our client payors and their aggregate member lives;

• an array of administrative and back-office services, such as collections and appeals; and

• increased claims volume through various "soft steerage" mechanisms.

Because we have the ability to increase our client base and our network of ancillary service providers, we can grow revenue by increasing demand as well as increasing supply. New client relationships add new member lives that will seek ancillary services, while new service provider relationships create opportunities for new and existing member lives to receive additional incremental services.

The Company's revenues continued to decline as its revenues from its two most significant clients declined. Our most significant client lost a key relationship with a large employer group, while our other significant client continued its transition plan as part of a business combination. Those factors resulted in a combined 43% decline in revenue from the two relationships compared to 2010. In addition, unlike 2010, our sales cycle lengthened and we sold 4 new accounts in 2011, as compared to 13 new accounts sold in 2010. The sales cycle was negatively impacted by the competitive nature of negotiating with TPA's and direct payors, turnover in our sales and marketing function and prospects' conflicting priorities, primarily related to technology compliance projects. In light of our declining revenues, we have attempted to maintain, and where appropriate reduce, our non-variable costs for the primary purpose of maintaining our current cash reserves. In 2011, our non-variable costs (claims administration, provider development and selling, general and administrative expenses) declined 5%, from $10.7 million in 2010, to $10.1 million, excluding the impact of severance charges. In addition, we spent approximately $85,000 of consulting fees during late-2011 related to the analysis of various strategic initiatives related to our mix of services, development of new services and programs, and sales and marketing efforts.

1

ACS was incorporated under the laws of the State of Delaware on November 24, 2003 as a wholly-owned subsidiary of Patient Infosystems, Inc. (“Patient Infosystems”) in order to facilitate Patient Infosystems’ acquisition of substantially all of the assets of American CareSource Corporation.  American CareSource Corporation had been in operation since 1997.  The predecessor company to American CareSource Corporation, Physician’s Referral Network, had been in operation since 1995.  On December 23, 2005, the Company became an independent company when Patient Infosystems distributed by dividend to its stockholders substantially all of its shares of the Company. Ancillary Care Services, Inc. is a wholly owned subsidiary of the Company.

The Company’s principal executive offices are located at 5429 Lyndon B. Johnson Freeway, Suite 850, Dallas, TX 75240. Our Common Stock is listed on The NASDAQ Capital Market under the symbol “ANCI.” Our telephone number is (972) 308-6830.  Our Internet address is www.anci-care.com.

Services and Capabilities

Ancillary care services

Ancillary healthcare services include a broad array of services that supplement or support the care provided by hospitals and physicians, including the non-hospital, non-physician services associated with surgery centers, free-standing diagnostic imaging centers, home health and infusion, supply of durable medical equipment, orthotics and prosthetics, laboratory and other services.

Ancillary healthcare services include, but are not limited to, the following categories:

·      Acupuncture	·      Massage Therapy
·      Cardiac Monitoring	·      Occupational Therapy
·      Chiropractor	·      Orthotics and Prosthetics
·      Diagnostic Imaging	·      Pain Management
·      Dialysis	·      Physical Therapy
·      Durable Medical Equipment	·      Podiatry
·      Genetic Testing	·      Rehab: Outpatient
·      Hearing Aids	·      Rehab: Inpatient
·      Home Health	·      Sleep
·      Hospice	·      Skilled Nursing Facility
·      Implantable Devices	·      Surgery Center
·      Infusion	·      Transportation
·      Laboratory	·      Urgent Care
·      Lithotripsy	·      Vision
·      Long-term Acute Care	·      Walk-in Clinics

The Company has agreements with approximately 4,800 ancillary healthcare service providers operating in approximately 37,000 sites nationwide.

Provider Network

The Company views its ability to manage, organize and maintain its provider network and to recruit new providers as critical elements in its long-term success because its network is one of the most important reasons healthcare payors engage the Company.  The Company has agreements with its network of ancillary healthcare service providers for the purpose of meeting contractual obligations to its healthcare payors to make available a comprehensive and client-specific ancillary healthcare provider network.  The agreements define the scope of services to be provided to covered persons by each ancillary healthcare provider and the amounts to be charged for those services and are negotiated independently from the agreements reached with the Company’s client payors.  The terms of each agreement between the Company and ancillary healthcare service providers make it clear that the Company is solely obligated to the service provider under the contract between them and do not contemplate any contractual relationship between the service providers and the Company’s payors or permit the service providers to pursue claims directly against the Company’s payors.  

2

When providers initially enter the ACS provider network, the Company credentials them for inclusion in the Credentialed ACS Network.  The Company also re-credentials its providers on a periodic basis.  From time to time, the Company reviews its provider relationships to determine whether any changes to the relationship are appropriate through sanction monitoring and other methods.  The Company believes that credentialing providers represents a valuable service to both its payors and the providers in the network, who would, in the absence of such service, be forced to undergo the credentialing process with respect to each payor with whom they enter into a service relationship.

During 2011 and 2010, we generated revenue from ancillary healthcare services as follows:

Category	2011		2010
Dialysis	24	%	28	%
Laboratory	18		19
Durable Medical Equipment	14		13
Infusion	10		7
Diagnostic Imaging	9		10
Rehabilitation (outpatient & inpatient)	7		6
Surgery Center	6		4
Chiropractor	2		3
Long Term Acute Care/Skilled Nursing Facilities	2		2
Orthotics and Prosthetics	2		2
Other	6		6
	100	%	100	%

Our Model

The Company’s business model, illustrating the relationships among the persons involved, directly or indirectly, in the Company’s business and its generation of revenue and expenses is depicted below:

3

Payors route healthcare claims to us after service has been performed by participant providers in our network.  We process those claims and charge the payor according to its contractual rate for the services according to our contract with the payor.  In processing the claim, we are paid directly by the payor or the insurer for the service.  We then pay the provider of service according to its independently-negotiated contractual rate.  We assume the risk of generating positive margin, the difference between the payment we receive for the service and the amount we are obligated to pay the provider of service.

The Company may receive a claims submission from a payor either electronically or via a paper based claim.  As part of its relationship with the payors, the Company may pay an administrative fee to the payors for the modifications that may be required to the payor’s technology, systems and processes to create electronic connectivity with the Company, as well as for the aggregation of claims and the electronic transmission of those claims to us.

How We Deliver Services

Ancillary network analysis.  The Company performs an analysis of the available claims history from each client payor and develops a specific plan to meet each payor’s needs.  This analysis identifies service providers that are not already in our network.  We attempt to enter into agreements with such service providers to maximize discount levels and capture a significant volume of previously out-of-network claims.

Ancillary custom network.   ACS customizes its network to meet the needs of each payor.  In particular, when a new payor joins and periodically for each existing payor, we review the payor’s “out-of-network” claims history through our network analysis service and develop a strategy to create a network that efficiently serves the payor’s needs.  This may involve adding additional service providers for a payor or removing service providers if we determine it is beneficial for them to be excluded from the client’s network.

Ancillary network management.  The Company manages ancillary service provider contracts, reimbursement and credentialing for its payors.  This not only provides administrative benefits to our payors, but reduces the burden on our contracted service providers who typically must supply credentialing documentation to payors and engage in contract negotiations with separate payors.

Ancillary systems integration.  The Company has created a proprietary software system that enables us to manage many different customized accounts and includes the following modules:

• Provider network management

• Credentialing

• Data transfer management/electronic data interface

• Multi-level reimbursement management

• Posting, Explanation of Benefits, check, and e-funds processes

• Client service management

• Claims pricing

• Advanced data reporting

Ancillary reporting.  ACS offers a complete suite of reports to each payor on a monthly basis.  These reports cover contracting efforts and capture rates, client savings, volumes by service category and complete claims and utilization reports and other information of value to the client.

4

Ancillary healthcare claims management.  The Company can manage ancillary healthcare claims flow, both electronic and paper based, and integrate with a payor’s process electronically or through paper claims.  The Company has the capability of performing a number of customized processes that may add additional value for each payor.  As part of the claims management process, we manage the documentation requirements specific to each payor.  In the event claims are submitted to us by a payor without the complete required documentation, we will work with the payor and/or service provider to obtain the required documentation so that the claim will be accepted by the payor.  This service provides a labor cost savings to the payors and providers.

Ancillary claims collections management.  The Company facilitates an expedited claims collection process by ensuring receipt of the claim by the payor, providing information to the payor required for processing the claim, tracking the status of the claim throughout the process and maintaining a team of customer service representatives to resolve any issues that might delay the collections process.  The Company believes that the providers in its network are paid more effectively and efficiently than would otherwise be the case.

Ancillary data insights.  The Company has developed and continues to develop an extensive database of ancillary healthcare claims history.  The data provides insights into utilization and pricing across a wide variety of service categories, geographies, and service providers.  The Company has the ability to market this data as a value added service to its payors in the design of custom networks, and the development of ancillary healthcare management programs.

Business Strategy

The Company’s focus is strictly on the ancillary healthcare services market, a growing market that now accounts for between 20-30% of total annual healthcare spending in the United States and was estimated at $574 billion (as derived from 2006 data published by the Center for Medicare and Medicaid Services, National Health Statistics Group, U.S. Department of Commerce and Bureau of Economic Analysis and Census).   Ancillary healthcare services are cost effective alternatives to physician and hospital-based services and ancillary providers offer services in 30 different categories, including those listed under “-- Services and Capabilities--Ancillary care services.”  While most efforts are placed on managing outcomes and reducing healthcare costs associated with patient care in hospitals and in physician offices, the ancillary healthcare service market is an often over-looked, but very important emerging segment of the overall United States healthcare system.  As more and more care is delivered in highly cost effective out-patient and ancillary care settings, the need for better organization and cost containment will only increase over the next several years.  

We believe that companies who understand the nuances of the ancillary healthcare market and develop the expertise to manage this de-centralized system of patient care, are able to capitalize on this market opportunity.  For example, contracting with ancillary healthcare service providers is difficult without a specific focus on the market.  This is due to the disparate nature of ancillary healthcare services and the fact that these services are offered by a wide array of providers, ranging from small independent practitioners to regional specialty practices, national providers and providers within hospital systems.  Since this market is so diverse, it has not been a focus of the major health plans and payors.  In addition, many health plans are conflicted because their existing hospital contracts may encourage the use of the hospital systems’ more expensive in-house ancillary services.  The Company believes that because it has developed a substantial network of providers, it has established a sustainable advantage in this market by becoming an aggregator of these services for health plans, and because it has been retained by substantial payors, it can offer healthcare providers a substantial number of patients who are entitled to receive services from payors.  In addition, our "ancillary only" contracting focus allows us to be independent of any hospital relationships that may encourage retaining all ancillary services within the more expensive hospital setting.

Because the Company is solely focused on the nation-wide ancillary healthcare system designed specifically to help regional and mid-market payors across the country, expanding and maintaining a nation-wide, high-quality, multiple specialty ancillary provider network is a critical component of the Company’s strategy.  The Company has invested to develop its ancillary service provider network both proactively, across geographical and healthcare specialties, and reactively to address specific client needs.  While we have a national footprint of service providers, our intention is to focus on specific geographic markets where we can have a significant impact on a service provider’s patient load.  With market strength in specific geographic areas, the Company has been able to develop favorable rates with ancillary service providers and create an attractive product offering (healthcare cost savings) to regionally-based clients in those areas.

5

In order to enhance its ability to recruit and manage its network of providers, the Company offers a suite of value added services specifically designed to help ancillary care service providers lower their cost of doing business by assuming the responsibility for the most complex and costly interactions with payors.  The services include those listed under “-- Services and Capabilities--Ancillary care services.”   The Company believes that by becoming an indispensable business partner to the ancillary healthcare service provider community, it will continue to grow its ancillary healthcare service provider network and continue to derive favorable contracting terms from these service providers.

While the Company markets its services to PPOs on an opportunistic basis, it is seeking growth from increasing its number of client payor and service provider relationships by focusing on providing in-network services for its payors and aggressively pursuing TPAs, insurance companies, large self-funded organizations and employee groups. The Company continues to derive a significant amount of its net revenues from its traditional PPO relationships, but we have shifted our focus and we now aggressively target TPAs and direct payors.    There are approximately 500 TPAs nationwide, with approximately 50 being our target market. In addition, according to research reported by the Employee Benefit Research Institute, as recently as 2008, approximately 55% of employees with health insurance were covered by a self-insured plan. Thus, the Company believes that there is a large market opportunity involved in providing a highly competitive ancillary care solution to the standard service offered by the major national insurers in select regional markets across the country.  The combination of our regionally specific networks of providers and the resulting contractual cost savings we are able to generate helps ACS’ payors compete more effectively against the major national insurers in their local markets.

The Company aggregates the lives of its various clients into buying power that exceeds the market power of any one of its clients individually. During 2011, the Company's contracts exposed us to an estimated 2.5 million covered lives. As a rapid aggregator of significant patient volume, the Company believes it will be able to continue to drive favorable contracting terms from the selected service providers in the ACS Network by directing patient volume to their practices and it will have the ability to negotiate exclusive contracts that will allow the Company to manage the full spectrum of a payor client’s ancillary healthcare benefit offerings.  The volume of collective lives we manage allows us to obtain more favorable pricing than our clients can generally obtain on their own. 

Sales and Marketing

The Company markets its services to PPOs on an opportunistic basis, but primarily targets direct payors such as TPAs, insurance companies, large self-funded organizations and employee groups.  Currently, the Company utilizes both a new business sales organization of five senior sales professionals as well as an account management team of two professionals to contract with new payor organizations and then maximize the revenue and margin potential of each new payor.  The new business sales team uses a variety of channels to reach potential clients including professional relationships, direct marketing efforts, attendance at industry-specific trade shows and conferences, and through strategic partnerships with market partners, independent brokers, and consultants.  The account management team is engaged with each new payor to help manage the implementation process.  In addition, an Account Manager is generally assigned to each new payor organization and is responsible for all aspects of the Company’s relationship with the entity including the expanded utilization of the Company’s services over time and the enhancement of the Company’s relationship with the payor.

Clients

The Company’s healthcare payor clients engage the Company to manage a comprehensive array of ancillary healthcare services that they and their payors have agreed to make available to their insureds or beneficiaries or for which they have agreed to provide insurance coverage.  The typical services the healthcare payors require the Company to provide include:

• providing a comprehensive network of ancillary healthcare services providers that is available to the payor’s covered persons for covered services;

• providing claims management, reporting, and processing and payment services;

• performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor-specific provider networks; and

• credentialing network service providers for inclusion in the payor-specific provider networks.

6

The terms of the agreement between the Company and the payors do not contemplate that the payors will have any relationship with the service providers and, in fact, prohibit payors from claiming directly against the service providers.  The agreements between the Company and the payors provide that it is the Company’s obligation to deliver or make available the agreed-upon services.  The Company is responsible irrespective of the existence or terms of any agreement the Company has with the service providers.  The terms of the Company-payor agreement provide that the Company is obligated to provide or arrange for the provision of all of the services covered by such agreement and the Company is responsible for ensuring that the contractual terms are met and such services are provided (whether the services are those performed directly by the Company, such as claims management, processing and payment service, network/needs analysis and credentialing, or those performed by a service provider contracted by the Company).

The Company’s most significant payors include (i) HealthSmart (“HealthSmart”), which consists of HealthSmart and its affiliates, American Administrative Group (“AAG”), Interplan Health Group (“IHG”), Emerald Healthcare, and HealthSmart Accel Network (“Accel”), and (ii) Viant Holdings Inc. (“Viant”), consisting of Texas True Choice, Inc. and Beech Street Corporation.  For the years ended December 31, 2011 and 2010, ACS derived 34% and 48%, respectively, of its total net revenue from HealthSmart (including its affiliates) and 20% and 27%, respectively, of its total net revenue from Viant (including its affiliates).

In late 2008, we entered into an amendment to our agreement with HealthSmart. The amendment extended the duration of the partnership between the Company and HealthSmart through December 31, 2012. In accordance with the amendment, we paid $1.0 million to HealthSmart for various integration services. In November 2009, HealthSmart completed a recapitalization with a private investment company and HealthSmart’s other lenders.  

The client contract with Viant expired on May 20, 2011 but automatically renewed for a one-year period and for successive one year periods unless either party delivers a written notice of non-renewal at least 90 days prior to expiration.  Since the Company has not received written notice of non-renewal, the contract term has been automatically extended through May 20, 2013. Such contract may be terminated upon thirty (30) days’ notice in the event of a breach.  In March 2010, Viant was acquired by MultiPlan, Inc. ("MultipPlan"), a provider of PPO network and related transaction-based solutions. Subsequent to the business combination, our client began to migrate its payors and employee groups to network alternatives, negatively impacting claims volume from our client. We anticipate the transition to continue through 2012 and be complete by December 31, 2012, which will significantly impact our revenue and claims volume from the client.

We have generated a significant portion of our net revenues from these two clients (54% in 2011 and 75% in 2010), but because of the nature of the relationships, we do not have the ability to competitively impact the relationships these organizations have with their clients, which are direct payors. Because we have secondary relationships with these payors and cannot have a competitive impact on the payors, we have determined that it is in our best interest to pursue clients that are direct payors, primarily TPAs. We believe we can impact relationships with direct payors through various competitive avenues, such as assisting them with more competitive pricing and plan design. During the past two years, of our 17 new clients, 16 were direct payors and TPAs. While we experienced obstacles to acquiring new client accounts in 2011, we believe that the ancillary savings and the reimbursement paid to clients for connectivity and maintaining electronic claims flow provide a solid value proposition to prospective clients and will enable us to penetrate the national TPA market in 2012.

Competition

The Company faces four types of direct competitors.

• The first group of competitors consists of larger, national health plans and insurers such as Aetna, Blue Cross/Blue Shield plans, Cigna, Humana, and United HealthCare.  These larger carriers offer nation-wide, standardized products and often compete on a local level based of the cost-effectiveness of their national contracts.

• The second group of competitors is our own payors.  Our payors have selected us based on our extensive network of service providers and cost-savings potential.  However, they may choose to develop their own network instead of outsourcing ancillary management services to us in the future.

• The third group of competitors is more regionally-focused and consists of smaller regional PPOs, payors and community-based provider-owned networks.  These regional competitors are generally managing their own home-grown network of ancillary care providers and are more likely to offer customized products and services tailored to the needs of the local community.  These regional groups will often use their ownership and/or management of the full continuum of care in a local market to direct patients to the provider groups within their network.

7

• The fourth group of competitors focus on managing patients within a single ancillary specialty (e.g. dialysis, imaging or infusion), and offer comprehensive payor and provider services within their chosen ancillary category.

Research and Development

The Company invests in its information technology infrastructure to enhance the capabilities of its databases, data retrieval tools, data exchange capabilities and claims processing engine.  In addition, the Company believes that its extensive claims database of ancillary healthcare services and costs is a strategic asset.  The Company’s capitalized development costs totaled approximately $611,000 and $402,000 during 2011 and 2010, respectively. The development expenses during those periods was related primarily to enhancement made to our internal repricing engine. The enhancements allow the Company to develop and launch a variety of innovative products and services as well as gain competitive market advantage through faster and more accurate claims processing.

Government Regulation

The healthcare industry is extensively regulated by both the Federal and state governments.  A number of states have extensive licensing and other regulatory requirements applicable to companies that provide healthcare services.  Additionally, services provided to health benefit plans in certain cases are subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Furthermore, state laws govern the confidentiality of patient information through statutes and regulations that safeguard privacy rights.  The Company is subject to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which provides national standards for electronic health information transactions and the data elements used in such transactions.  ACS and its clients may be subject to Federal and state laws and regulations that govern financial and other arrangements among healthcare providers.  Furthermore, the Company and its clients may be subject to federal and state laws and regulations governing the submission of false healthcare claims to the government and private payors, mail pharmacy laws and regulations, consumer protection laws and regulations, legislation imposing benefit plan design restrictions, various licensure laws, such as managed care and third party administrator licensure laws, drug pricing legislation, and Medicare and Medicaid reimbursement regulations.  Possible sanctions for violations of these laws and regulations include minimum civil penalties of between $5,000-$10,000 for each false claim and treble damages.

During 2010, President Obama signed the Patient Protection and Affordable Care Act (the "Affordable Care Act") and the Health Care and Educational Affordability Reconciliation Act legislating broad-based changes to the U.S. health care system. Among other things, the health reform legislation includes guaranteed coverage requirements, eliminates pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, and imposes new and significant taxes on health insurers and health care benefits.

Provisions of the health reform legislation become effective at various dates over the next several years.  The Department of Health and Human Services ("HHS"), the National Association of Insurance Commissioners, the Department of Labor and the Treasury Department have yet to issue some of the necessary enabling regulations and guidance with respect to the health care reform legislation.

Due to the breadth and complexity of the health reform legislation, the scope of implementing regulations and interpretive guidance, in addition to regulations and guidance yet to be issued, the phased-in nature of the implementation, litigation challenging the constitutionality of the legislation pending before the U.S. Supreme Court and possible changes to, or repeal of, the legislation by Congress, it is difficult to predict the overall impact of the health reform legislation on our business over the coming years.  Possible adverse affects of the health reform legislation include reduced revenues, increased costs, exposure to expanded liability, and requirements for us to revise the ways in which we conduct business or risk of loss of business.  In addition, our results of operations, our financial position and cash flows could be materially adversely affected.

8

Section 1001 of the Affordable Care Act amended Title 27 of the Public Health Service Act of 1994, as amended (the "Public Health Service Act") to add, among other things, a new Section 2718, 'Bringing Down the Cost of Health Care Coverage.' This new provision requires health insurance issuers to publicly report “the ratio of the incurred loss (or incurred claims) plus the loss adjustment expense (or change in contract reserves) to earned premiums” and account for premium revenue related to reimbursement for clinical services, activities that improve health care quality, and all other non-claims costs. The law also requires issuers to provide annual rebates to their enrollees if their medical loss ratio ("MLR") does not meet specific targets. For issuers in the large group market, the MLR must be at least 85%, and for issuers in the smaller and individual markets, the MLR must be at least 80%. The law also gives the National Association of Insurance Commissioners (“NAIC”), subject to certification of the Secretary of the HHS, authority to develop definitions and standards by which to determine compliance with the requirements in the new § 2718(a).

On December 1, 2010, HHS published final MLR regulations, based upon the recommendations of the NAIC, implementing the new sections of the Public Health Service Act as mandated by the Affordable Care Act.  The new regulations apply to issuers offering group or individual health insurance coverage. Under the MLR regulations, an issuer's MLR is calculated as the ratio of (i) incurred claims plus expenditures for activities that improve health care quality to (ii) premium revenue.  The two key aspects to this calculation involve what comprises an 'incurred claim' and what qualifies as an 'expenditure for health care quality improvement.' 

Incurred claims are reimbursement for clinical services, subject to specific deductions and exclusions.  Specifically, incurred claims represent the total of direct paid claims, unpaid claim reserves, change in contract reserves, reserves for contingent benefits, the claim portion of lawsuits and any experience rating refunds. Prescription drug rebates received by the issuer and overpayment recoveries from providers must be deducted from incurred claims.  Also, the following amounts are explicitly excluded and therefore may not be included in the calculation of incurred claims:  (i) amounts paid to third party vendors for secondary network savings; (ii) amounts paid to third party vendors for network development, administrative fees, claims processing, and utilization management; or (iii) amounts paid, including amounts paid to a provider, for professional or administrative services that do not represent compensation or reimbursement for covered services provided to an enrollee. The regulation permits that some amounts “may” be included in incurred claims - market stabilization payments, state subsidies based on stop-loss methodologies, and incentive and bonus payments made to providers.  The regulations themselves provide examples of specifically excluded amounts. With regard to amounts paid for network development (as noted in (ii) above), if an issuer contracts with a behavioral health, chiropractic network, or high technology radiology vendor, or a pharmacy benefit manager, and the vendor reimburses the provider at one amount but bills the issuer a higher amount to cover its network development, utilization management costs, and profits, then the amount that exceeds the reimbursement to the provider must not be included in incurred claims. With regard to administrative services (as noted in (iii) above), medical record copying costs, attorneys' fees, subrogation vendor fees, compensation to paraprofessionals, janitors, quality assurance analysts, administrative supervisors, secretaries to medical personnel and medical record clerks must not be included in incurred claims.

In order to properly classify what activities 'improve health care quality', the activity must be designed to improve health quality, increase the likelihood of desired health outcomes, be directed toward individual enrollees or incurred for the benefit of specific segments of enrollees, or be grounded in evidence based medicine. In addition, the activity must be primarily designed to improve health outcomes, prevent hospital readmissions, improve patient safety and reduce medical errors, implement, promote and increase wellness activities and/or enhance the use of health care data to improve quality.  The regulations also contain a list of 14 expenditures that are specifically excluded from 'improvement of health care quality' activities. Among these excluded expenditures are: (1) those that are designed primarily to control or contain costs; (2) activities that can be billed or allocated by a provider for care delivery and which are, therefore, reimbursed as clinical services; (3) expenditures related to establishing or maintaining a claims adjudication system, including costs directly related to upgrades in health information technology that are designed primarily or solely to improve claims payment capabilities or to meet regulatory requirements for processing claims (for example, costs of implementing new administrative simplification standards and code sets adopted pursuant to HIPAA including the new ICD-10 requirements); (4) all retrospective and concurrent utilization review; (5) costs of developing and executing provider contracts and fees associated with establishing or managing a provider network, including fees paid to a vendor for the same reason; (6) provider credentialing; (7) marketing expenses; (8) costs associated with calculating and administering individual enrollee or employee incentives; (9) portions of prospective utilization that does not meet the definition of activities that improve health quality; and (10) any function or activity not expressly included, unless otherwise approved by and within the discretion of the Secretary.

It is possible that a portion of the fees our existing and prospective payors are contractually required to pay us and that do not qualify as 'incurred claims' may not be included as expenditures for activities that improve health care quality. Such a determination may make it more difficult for us to retain existing clients and/or add new clients,because our clients' or prospective clients' MLR may otherwise not meet the specified targets. This may reduce our net revenues and profit margins.

9

The Company must continually adapt to new and changing regulations in the healthcare industry. If we fail to comply with these applicable laws, we may be subject to fines, civil penalties, or criminal prosecution.  If an enforcement action were to occur, our business and financial condition may be adversely affected.

Employees

As of March 5, 2012, the Company had 56 full-time employees and no part-time employees.

Item 1A.                     Risk Factors.

The Company’s stockholders and any potential investor in the Company’s Common Stock should carefully review and consider each of the following risk factors, as well as all other information appearing in this Annual Report on Form 10-K, relating to investment in our Common Stock.  The Company’s business faces numerous risks and uncertainties, the most significant of which are described below.  If any of the following risks actually occur, the business, financial condition, results of operations or cash flows of the Company could be materially adversely affected, the market price of the Company’s Common Stock could decline significantly, and a stockholder could lose all or part of an investment in the Company’s Common Stock.

The Company has two clients which account for a substantial portion of its business, and failure to retain such clients or changes to these clients would have a material adverse effect on its business and results of operations. Business from these two clients has declined during the last three years, and will likely continue to decline.

Our two largest clients, HealthSmart Preferred Care, Inc. (together with its affiliates, “HealthSmart”) and Viant Holdings, Inc. (together with its affiliates, “Viant”), accounted for an aggregate of approximately 54% of our net revenue during 2011; of which 34%was derived from HealthSmart.  In 2010, our two largest clients accounted for 75% of our net revenue, of which 48% was generated from HealthSmart. The loss of either one of these clients or significant declines in the level of use of our services by one or more of these clients (as would be the case, for example, if our clients decide to contract directly with ancillary healthcare service providers), without replacement by new business, would have a material adverse effect on the Company’s business and results of operations. Our 2011 revenue from HealthSmart and Viant declined by an aggregate of 43% from its 2010 level.

The client contract with Viant expired on May 20, 2011 but automatically renewed for a one-year period and renews for successive one-year periods unless either party delivers a written notice of non-renewal at least 90 days prior to expiration.  Since the Company has not received written notice of non-renewal, the contract term has been automatically extended through May 20, 2013. Such contract may be terminated upon thirty (30) days’ notice in the event of a breach.  In addition, in March 2010, Viant was acquired by MultiPlan, Inc., a provider of PPO network and related transaction-based solutions. We expect that revenue from Viant will continue to decline as its business is integrated with its acquiror, which we anticipate will be complete by December 31, 2012. We expect this to have a significant impact on revenue generated from the client.

The client contract with HealthSmart will expire on December 31, 2012.  There can be no assurance that any client will maintain its contract with us after the expiration of the then-current term or that it will renew its contract on terms favorable to us.  In addition, HealthSmart lost an employer group effective January 1, 2011. The group accounted for approximately $9.8 million of revenue to the Company in 2010. If either of these clients loses more significant revenue sources, there will be a material impact on our revenue and results of operations.

The Company’s failure to retain such clients could have a material adverse effect on its business and results of operations.  Additionally, an adverse change in the financial condition of any of these clients, particularly HealthSmart, including an adverse change as a result of a change in governmental or private reimbursement programs, could have a material adverse effect on our business and results of operations.

10

Recent and pending health care reforms could materially adversely affect our revenues, financial position and our results of operations.

The enactment and implementation of health care reforms at the federal or state level may affect certain aspects of our business, including contracting with ancillary healthcare service providers; administrative, technology or other costs; provider reimbursement methods and payment rates; premium rates; coverage determinations; mandated benefits; minimum medical expenditures; claim payments and processing; drug utilization and patient safety efforts; collection, use, disclosure, maintenance and disposal of individually identifiable health information; personal health records; consumer-driven health plans and health savings accounts and insurance market reforms; and government-sponsored programs.

During 2010, President Obama signed the Affordable Care Act and the Health Care and Educational Affordability Reconciliation Act legislating broad-based changes to the U.S. health care system. Among other things, the health reform legislation includes guaranteed coverage requirements, eliminates pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, and imposes new and significant taxes on health insurers and health care benefits.

On December 1, 2010, HHS published final regulations implementing new sections of the Public Health Service Act as mandated by the Affordable Care Act. The new medical loss ratio ("MLR") regulations apply to issuers offering group or individual health insurance coverage. Under the MLR regulations, an issuer's MLR is calculated as the ratio of (i) incurred claims plus expenditures for activities that improve health care quality to (ii) premium revenue.  The two key aspects to this calculation involve what comprises an 'incurred claim' and what qualifies as an 'expenditure for health care quality improvement.'  It is possible that a portion of the fees our existing and prospective payors are contractually required to pay us and that do not qualify as 'incurred claims' may not be included as expenditures for activities that improve health care quality. Such a determination may make it more difficult for us to retain existing clients and/or add new clients,because our clients' or prospective clients' MLR may otherwise not meet the specified targets. This may reduce our net revenues and profit margins.

Other provisions of the health reform legislation become effective at various dates over the next several years.  The Department of Health and Human Services, the National Association of Insurance Commissioners, the Department of Labor and the Treasury Department will issue additional enabling regulations and guidance with respect to the health care reform legislation.

Due to the breadth and complexity of the health reform legislation, the scope of implementing regulations and interpretive guidance, in addition to regulations and guidance yet to be issued, the phased-in nature of the implementation, litigation challenging the constitutionality of the legislation pending before the U.S. Supreme Court and possible changes to, or repeal of, the legislation by Congress, it is difficult to predict the overall impact of the health reform legislation on our business over the coming years.  Possible adverse affects of the health reform legislation include reduced revenues, increased costs, exposure to expanded liability, and requirements for us to revise the ways in which we conduct business or risk of loss of business.  In addition, our results of operations, our financial position and cash flows could be materially adversely affected.

The Company has a history of losses.

The Company incurred a net loss of $7.2 million in 2011 ($4.4 million of which related to a goodwill impairment charge), and it had an early history of losses in each year between its spinoff in 2003 through 2007. As of December 31, 2011, the Company has an accumulated deficit of approximately $8.2 million.  The Company will need to return to levels of claims volume and revenue as it had in 2008 through 2010 in order to return to profitability.  No assurances can be given that the Company's current operating volumes will not continue to decline in the future.  The Company’s prospects must be considered in light of the numerous risks, expenses, delays and difficulties frequently encountered in an industry characterized by intense competition, as well as the risks inherent in the development of new programs and the commercialization of new services.

The length of the current sales cycle may impede the Company's efforts to add new client accounts.

During 2010, the Company sold 13 new accounts, which accounted for $11.9 million or 24% of net revenue in 2011. During 2011, our sales cycle lengthened and we sold only 4 new accounts. The sales cycle was negatively impacted by the competitive nature of negotiating with TPA's and direct payors, turnover in our sales and marketing function and prospects' conflicting priorities, primarily related to technology compliance projects. Despite efforts to strategically improve our sales and marketing function, we can give no assurances that it will not continue to be a lengthy process to convert a sales prospect into a new client account and that our revenues will not continue to decline due to the lack of new client accounts.

11

The current state of the global economy may reduce our revenue and profitability and harm our growth prospects.

The Company's results have been impacted by the current economic state.  First, the unemployment rate has caused fewer people to participate in insurance programs with our clients.  Second, plan participants, seeking to spend less money, appear to be making less frequent use of some ancillary services.  Third, client and/or provider consolidation within our industry could adversely affect our business.  To the extent that these trends continue, or become worse, we may receive less revenue and our profitability and growth could be adversely affected, depending on the extent of the declines.  Finally, as with any business, the deterioration of the financial condition or sale or change of control of our significant clients could have a corresponding adverse effect on us.

Large competitors in the healthcare industry could choose to compete with us, reducing our margins. Some of these potential competitors may be our current clients.

Traditional health insurance companies, specialty provider networks, and specialty healthcare services companies are potential competitors of the Company.  These entities include well-established companies that may have greater financial, marketing and technological resources than we have. Pricing pressure caused by competition has caused many of these companies to reduce the prices charged to clients for core services and to pass on to clients a larger portion of the formulary fees and related revenues received from service providers.  Increased price competition from such companies’ entry into the market could reduce our margins and have a material adverse effect on our financial condition and results of operations.  In fact, our clients could choose to establish their own network of ancillary care providers.  As a result, we would not only lose the benefit of revenue from such clients, but we could face additional competition in our market.

The Company is dependent upon payments from third party payors who may reduce rates of reimbursement.

The Company’s profitability depends on payments provided by third-party payors.  Competition for patients, efforts by traditional third party payors to contain or reduce healthcare costs and the increasing influence of managed care payors, such as health maintenance organizations, have resulted in reduced rates of reimbursement in recent years.  If continuing, these trends could adversely affect the Company’s results of operations unless it can implement measures to offset the loss of revenues and decreased profitability. In addition, changes in reimbursement policies of private and governmental third-party payors, including policies relating to the Medicare and Medicaid programs, could reduce the amounts reimbursed to the Company’s clients for the Company’s services provided through the Company, and consequently, the amount these clients would be willing to pay for the Company’s services. Also, under the MLR regulations included in the Affordable Care Act, it is possible that a portion of the fees our existing and prospective payors are contractually required to pay us and that do not qualify as 'incurred claims' may not be included as expenditures for activities that improve health care quality. Such a determination may make it more difficult for us to retain existing clients and/or add new clients,because our clients' or prospective clients' MLR may otherwise not meet the specified targets. This may reduce our net revenues and profit margins.

The Company is dependent upon its network of qualified providers and its provider agreements may be terminated at any time.

The development of a network of qualified providers is an essential component of our business strategy.   The typical form of agreement from ancillary healthcare providers provides that these agreements may be terminated at any time by either party with or without cause.  If these agreements are terminated, such ancillary healthcare providers could enter into new agreements with our competitors which would have an adverse effect on our ability to continue our business as it is currently conducted.

For any given claim, the Company is subject to the risk of paying more to the provider than it receives from the payor.

The Company’s agreements with its payors, on the one hand, and the service providers, on the other, are negotiated separately.  The Company has complete discretion in negotiating both the prices it charges its payors and the financial terms of its agreements with the providers.  As a result, the Company’s profit is primarily a function of the spread between the prices it has agreed to pay the service providers and the prices the Company’s payors have agreed to pay the Company.  The Company bears the pricing/margin risk because it is responsible for providing the agreed-upon services to its payors, whether or not it is able to negotiate fees and other agreement terms with service providers that result in a positive margin for the Company.  For example, during 2011 and 2010, approximately 5% and 7%, respectively, of claims were “loss claims” (that is, where the amount paid by the Company to the provider exceeded the amount received by the Company from the corresponding payor for that particular claim) and these loss claims, in the aggregate, comprised approximately $512,000 and $1.0 million in 2011 and 2010, respectively. There can be no assurances that the loss claim percentage will not be higher in future periods.  If a higher percentage of the Company’s claims resulted in a loss, its results of operations and financial position would be adversely affected.

12

An interruption of data processing capabilities and telecommunications could negatively impact the Company’s operating results.

Our business is dependent upon our ability to store, retrieve, process and manage data and to maintain and upgrade our data processing capabilities.  An interruption of data processing capabilities for any extended length of time, loss of stored data, programming errors, other computer problems or interruptions of telephone service could have a material adverse effect on our business.

Changes in state and federal regulations could restrict our ability to conduct our business.

Numerous state and federal laws and regulations affect our business and operations. These laws and regulations include, but are not necessarily limited to:

• Public Health Services Act, Patient Protection and Affordable Care Act and Health Care and Educational Affordability Reconciliation Act;

• healthcare fraud and abuse laws and regulations, which prohibit illegal referral and other payments;

• the Employee Retirement Income Security Act of 1974 and related regulations, which regulate many healthcare plans;

• mail pharmacy laws and regulations;

• privacy and confidentiality laws and regulations;

• consumer protection laws and regulations;

• legislation imposing benefit plan design restrictions;

• various licensure laws, such as managed care and third party administrator licensure laws;

• drug pricing legislation;

• Medicare and Medicaid reimbursement regulations; and

• Health Insurance Portability and Accountability Act of 1996.

We believe we are operating our business in substantial compliance with all existing legal requirements material to the operation of our business. There are, however, significant uncertainties regarding the application of many of these legal requirements to our business, and there cannot be any assurance that a regulatory agency charged with enforcement of any of these laws or regulations will not interpret them differently or, if there is an enforcement action, that our interpretation would prevail.

If the Company fails to comply with the requirements of HIPAA, it could face sanctions and penalties.

HIPAA provides safeguards to ensure the integrity and confidentiality of health information. Violation of the standards is punishable by fines and, in the case of wrongful disclosure of individually identifiable health information, fines or imprisonment, or both. Although we provide thorough training to our employees and we intend to comply with all applicable laws and regulations regarding medical information privacy, failure to do so could have an adverse effect on our business.

Limited barriers to entry into the ancillary healthcare services market could result in greater competition.

There are limited barriers to entering our market, meaning that it is relatively easy for other companies to replicate our business model and provide the same or similar services that we currently provide. Major benefit management companies and healthcare companies not presently offering ancillary healthcare services may decide to enter the market. These companies may have greater financial, marketing and other resources than are available to us.  Competition from other companies may have a material adverse effect on our financial condition and results of operations.

13

The Company may be unsuccessful in hiring and retaining skilled employees.

The future growth of our business depends on our ability to hire and retain skilled employees.  The Company may be unable to hire and retain the skilled employees needed to succeed in our business.  Qualified employees are in great demand throughout the healthcare industry. Our failure to attract and retain sufficient skilled employees may limit the rate at which our business can grow, which will result in harm to our financial performance.  

An inability to adequately protect our intellectual property could harm the Company’s competitive position.

We consider our methodologies, processes and know-how to be proprietary. We seek to protect our proprietary information through confidentiality agreements with our employees, as well as our clients and contracted service providers.  The Company’s policy is to have its employees enter into a confidentiality agreement at the time employment begins, with the confidentiality agreement containing provisions prohibiting the employee from disclosing our confidential information to anyone outside of the Company, requiring the employee to acknowledge, and, if requested, assist in confirming the Company’s ownership of new ideas, developments, discoveries or inventions conceived by the employee during his or her employment with the Company, and requiring the assignment by the employee to the Company of proprietary rights to such matters that are related to our business. There can be no assurance that the steps taken by the Company to protect its intellectual property will be successful. If the Company does not adequately protect its intellectual property, its competitors may be able to use its technologies and erode or negate the Company’s competitive advantage in the market.

Fluctuations in the number and types of claims processed by the Company could make it more difficult to predict the Company’s net revenues from quarter to quarter.

Monthly fluctuations in the number of claims we process and the types of claims we process will impact the quarterly and annual results of the Company.  Our margins vary depending on the type of ancillary healthcare service provided, the rates associated with those services and the overall mix of these claims, each of which will impact our profitability.  Consequently, it may be difficult to predict our net revenue from one quarter to another quarter.

Future sales of the Company’s Common Stock, or the perception that these sales may occur, could depress the price of the Company’s Common Stock. 

Sales of substantial amounts of our Common Stock, or the perception in the public that such sales may occur, could cause the market price of the Company’s Common Stock to decline.  This could also impair the Company’s ability to raise additional capital through the sale of equity securities.  As of March 5, 2012, the Company had 17,075,662 shares of its Common Stock outstanding.  The outstanding shares are either freely tradable without restriction or further registration under the Securities Act, unless the shares are held by one of our “affiliates” as such term is defined in Rule 144 of the Securities Act, or are “restricted shares” as that term is defined under the Securities Act, and may be sold from time to time pursuant to a registration statement which was declared effective on February 8, 2007 by the Securities and Exchange Commission (the “SEC”), or in reliance upon an exemption from registration available under the Securities Act.  At March 5, 2012, warrants to purchase 358,334 shares of Common Stock of the Company were outstanding, and options to purchase 2,189,522 shares of Common Stock of the Company had been granted and were outstanding under the Company’s Amended and Restated 2005 Stock Option Plan and the 2009 Equity Incentive Plan.  At March 5, 2012, restricted stock units (“RSUs”) relating to 18,086 shares of common stock were outstanding under our 2009 Equity Incentive Plan.  In addition, an aggregate of 1,669,618 shares of the Common Stock of the Company remain available for future grants of RSUs, options and other equity under the Company’s Amended and Restated 2005 Stock Option Plan and 2009 Equity Incentive Plan.  If all of the outstanding warrants are exercised, all options available under the Company’s Amended and Restated 2005 Stock Option Plan and 2009 Equity Incentive Plan are issued and exercised and all RSUs are converted, there will be approximately 21,311,180 shares of Common Stock of the Company outstanding.

14

Some of our existing stockholders can exert control over us and may not make decisions that further the best interests of all stockholders.

As of March 5, 2012, our officers, directors and principal stockholders (greater than 5% stockholders) together control beneficially approximately 48.7% of the outstanding Common Stock of the Company.  As a result, these stockholders, if they act individually or together, may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions.  Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and, accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider.  In addition, this concentration of ownership of the Company’s Common Stock may delay or prevent a merger or acquisition resulting in a change in control of the Company and might affect the market price of our Common Stock, even when such a change in control may be in the best interest of all of our stockholders.

We are subject to the listing requirements of the NASDAQ Capital Market and there can be no assurances that we will continue to satisfy these listing requirements.

On September 21, 2011, the Company received a letter from NASDAQ stating that for 30 consecutive business days immediately preceding the date of the letter the Company's common stock did not maintain a minimum closing bid price of $1.00 per share (“Minimum Bid Price Requirement”) as required by NASDAQ Listing Rule 5550(a)(2).

Under the NASDAQ Listing Rules, if on or prior to March 19, 2012, the closing bid price of the Company's stock is at or above $1.00 for a minimum of 10 consecutive business days (subject to extension in the discretion of NASDAQ staff), the Company will regain compliance with the Minimum Bid Price Requirement. As of the date of this annual report on Form 10-K, the Company will not meet this requirement by March 19, 2012.

The Company will be afforded an additional 180-day compliance period, provided that on March 19, 2012 it meets the continued listing requirements for market value of publicly held shares (at least $1 million) and all other applicable standards for initial listing on the NASDAQ Capital Market (except for the Minimum Bid Price Requirement) and notifies NASDAQ of its intent to cure this deficiency. If it appears to NASDAQ staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, its common stock will be subject to delisting.

The Company continues to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the NASDAQ Listing Rules.

If we are delisted from The NASDAQ Capital Market and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or on the “pink sheets”. As a result, we could face significant adverse consequences including, among others,

• a limited availability of market quotations for our securities;

• a determination that our common stock is a "penny stock" which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

• a limited amount of news and analyst coverage for us; and

• a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3) or obtain additional financing in the future.

Item 2.                     Properties.

The Company occupies a total of 16,449 square feet of office space, all of which is leased.  The leased space comprises our principal executive offices, which is located at 5429 Lyndon B. Johnson Freeway, Suite 850, Dallas, TX 75240, pursuant to a lease that expires on March 31, 2013.  Included in the 16,449 square feet are 7,100 square feet of space added to our original lease by means of an amendment to the lease executed in February 2009.  This amendment stipulated on February 1, 2010, the premises would increase by 2,254 square feet increasing our total office space to 18,703 square feet. Late in 2011, the Company agreed to a partial termination by which the 2,254 square feet reverted back to the lessor. The Company does not own or lease any other real property and believes its offices are suitable to meet its current needs.

15

Item 3.                     Legal Proceedings.

None.

Item 4.                     Mine Safety Disclosures.

Not applicable.

16

PART II

Item 5.                     Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

The Company’s Common Stock has traded on The NASDAQ Capital Market (“NASDAQ”) under the symbol ANCI since September 29, 2008.  Between October 19, 2006 and September 26, 2008, our stock traded on the American Stock Exchange (“Amex”) under the symbol XSI and between December 28, 2005 and October 19, 2006, public trading of our Common Stock occurred on the OTC Bulletin Board.

The following table sets forth, for the fiscal periods indicated, the range of the high and low sales prices for our Common Stock on NASDAQ from January 1, 2010 through December 31, 2011.

	High		Low
2011
Fourth Quarter Ended December 31	$	0.74	$	0.30
Third Quarter Ended September 30	1.55		0.45
Second Quarter Ended June 30	1.90		1.35
First Quarter Ended March 31	1.95		1.38
2010
Fourth Quarter Ended December 31	$	1.62	$	1.30
Third Quarter Ended September 30	1.69		1.31
Second Quarter Ended June 30	2.20		1.55
First Quarter Ended March 31	2.91		1.46

The closing price on NASDAQ for our Common Stock on March 5, 2012 was $0.48.

On September 21, 2011, the Company received a letter from NASDAQ stating that for 30 consecutive business days immediately preceding the date of the letter the Company's common stock did not maintain a minimum closing bid price of $1.00 per share (“Minimum Bid Price Requirement”) as required by NASDAQ Listing Rule 5550(a)(2).

Under the NASDAQ Listing Rules, if on or prior to March 19, 2012, the closing bid price of the Company's stock is at or above $1.00 for a minimum of 10 consecutive business days (subject to extension in the discretion of NASDAQ staff), the Company will regain compliance with the Minimum Bid Price Requirement. As of the date of this annual report on Form 10-K, the Company will not meet this requirement by March 19, 2012.

The Company will be afforded an additional 180-day compliance period, provided that on March 19, 2012 it meets the continued listing requirements for market value of publicly held shares (at least $1 million) and all other applicable standards for initial listing on the NASDAQ Capital Market (except for the Minimum Bid Price Requirement) and notifies NASDAQ of its intent to cure this deficiency. If it appears to NASDAQ staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, its common stock will be subject to delisting.

The Company continues to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the NASDAQ Listing Rules.

Holders

As of March 5, 2012, in accordance with the records of our transfer agent, there were 131 record holders of ACS Common Stock. The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect holders of shares in “street name” or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.

17

Dividends

We have not declared cash dividends on our Common Stock.  We intend to retain all earnings to finance future growth and do not anticipate that we will pay cash dividends for the foreseeable future.

Securities Authorized for Issuance Under Equity Compensation Plans and Sales of Unregistered Securities

The information required to be disclosed herein is incorporated by reference to "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."

Repurchases of Securities

There were no repurchases of the Common Stock of the Company by or on behalf of the Company or any affiliated purchasers during the fourth quarter of the Company’s fiscal year ended December 31, 2011.

Item 7.                    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our consolidated financial statements, which present our results of operations for the twelve month periods ended December 31, 2011 and 2010 as well as our financial position at December 31, 2011 and 2010, contained elsewhere in this Annual Report on Form 10-K.  Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the “Special Note Regarding Forward Looking Statements” and “Risk Factors” sections of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

American CareSource Holdings, Inc. (“ACS,” “Company,”  the “Registrant,” “we,” “us,” or “our”) is an ancillary services company that offers cost effective access to a comprehensive national network of ancillary healthcare service providers.  The Company sells its services to a number of healthcare companies including preferred provider organizations ("PPOs"), third party administrators (“TPAs”), insurance companies, large self-funded organizations and various employee groups.  The Company offers payors this solution by:

• lowering its payors’ ancillary care costs throughout our network of high quality, cost effective providers that the Company has under contract at more favorable terms than the payors could generally obtain on their own; generally we provide our payor clients with 8-12% incremental savings on their ancillary healthcare services expenditures;

• providing payors with a comprehensive network of ancillary healthcare services providers that is tailored to each payor’s specific needs and is available to each payor’s covered persons for covered services;

• providing payors with claims management, reporting and processing and payment services;

• performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor -specific provider networks; and

• credentialing network service providers for inclusion in the payor -specific provider networks.  

Payors route healthcare claims to us after service has been performed by participant providers in our network.  We process those claims and charge the payor according to its contractual rate for the services according to our contract with the payor.  In processing the claim, we are paid directly by the payor or the insurer for the service.  We then pay the provider of service according to its independently-negotiated contractual rate.  We assume the risk of generating positive margin, the difference between the payment we receive for the service and the amount we are obligated to pay the provider of service.

18

The Company recognizes revenues for ancillary healthcare services when services by providers have been authorized and performed, the claim has been billed to the payor and collections from payors are reasonably assured.  Cost of revenues for ancillary healthcare services consist of amounts due to providers for providing ancillary health care services, client administration fees paid to our client payors to reimburse them for routing the claims to us for processing, and the Company’s related direct labor and overhead of processing invoices, collections and payments. The Company is not liable for costs incurred by independent contract service providers until payment is received by it from the payors. The Company recognizes actual or estimated liabilities to independent contract service providers as the related revenues are recognized.

The Company continues to seek growth in the number of client payors and service provider relationships it secures by focusing on providing in-network services for its payors and aggressively pursuing additional TPAs and other direct payors as its primary sales targets. The Company believes this strategy should increase the volume of claims the Company can process in addition to the expansion in the number of lives that are eligible to receive ancillary health care benefits.  The strategy should also increase the number of facilities available to existing and new members and thus increase our opportunity to capture claims volume. No assurances can be given that the Company can expand its service provider or payor relationships, nor that any such expansion will result in an improvement in the results of operations of the Company.

In addition, under the medical loss ratio ("MLR") regulations included in the Affordable Care Act, it is possible that a portion of the fees our existing and prospective payors are contractually required to pay us and that do not qualify as 'incurred claims' may not be included as expenditures for activities that improve health care quality. Such a determination may make it more difficult for us to retain existing clients and/or add new clients,because our clients' or prospective clients' MLR may otherwise not meet the specified targets. This may reduce our net revenues and profit margins.

Year Ended December 31, 2011 Compared to Year Ended December 31, 2010

Net Revenues

The Company’s net revenues are generated from ancillary healthcare service claims.  Revenue is recognized when we bill our client payors for services performed and collection is reasonably assured. The Company estimates revenues using average historical collection rates.  When estimating collectibility, we assess the impact of items such as non-covered benefits, denied claims, deductibles, co-payments and changes in the mix of payors, providers and service specialties utilized. Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected. There are no assurances that actual cash collections will meet or exceed estimated cash collections, as there are multiple variables that impact actual cash collections.

The following table sets forth a comparison of our net revenues for the following years ended December 31:

					Change
($ in thousands)	2011		2010		$			%
Net Revenues	$	48,906	$	61,201	$	(12,295	)	(20	)%

The decrease in net revenue for the year ended December 31, 2011 as compared to 2010 was due to an overall decline in claims volume, primarily from our two most significant clients. Claims volume declined 40% and 53% from the two clients, respectively, year-over-year.  

The following table sets forth a comparison of processed and billed claims for the years ended December 31:

	2011	2010
Claims processed (in thousands)	309	421
Claims billed (in thousands)	253	329

19

Overall claims volume declined due to the following factors:

• Loss of a large employer group by our most significant client, which is a PPO. Claims from the group generated revenue of approximately $9.8 million during 2010. Claims from the group generated only approximately $535,000 during 2011. In addition, our client experienced erosion in its remaining client base year-over-year as a result of various competitive factors;

• The ongoing transition status of our other significant account related to a business combination resulting in declining revenues and claims flow as our client transitions its payors and employer groups to network alternatives; we expect revenue from the account to be negatively impacted in 2012 by the transition, which we expect to be complete by December 31, 2012;

• Stronger presence of larger carriers in the market, which resulted in loss of market share;

• The change in patient and mix of provider specialties and benefit plan design changes, which has resulted in the increase in non-covered benefits, which negatively impacted collections on claims; and

• An extended sales cycle as we focus our sales efforts more heavily on the TPA and direct payor market. During 2010, we added 13 new client accounts as compared to four during 2011. The accounts added in 2010 generated approximately $5.9 million of revenue in 2010, compared to $1.0 million of revenue generated from the new accounts added in 2011. The sales cycle was extended due to (1) the inherent competitive nature of negotiating with TPA's; (2) turnover in our sales and marketing function; and (3) conflicting priorities on the part of sales prospects, primarily related to technology compliance projects.

The drop in claims volume resulted in a net $19.8 million, or 43%, decline in net revenues from our two significant clients.  The decline was partially offset by the following:

• $6.0 million of incremental revenue generated in 2011 from thirteen new clients implemented in 2010 (the clients generated $11.9 million and $5.9 million of revenue in 2011 and 2010, respectively); and

• A movement in the mix of provider specialties that generate revenue away from lower revenue-per-claim services, primarily as a result of the loss of a large employer group by our most significant client as discussed above.

 Despite the growth from the clients implemented in 2010, we continue to see revenue attrition in our two most significant client accounts, both of which are PPOs. Our second largest client continues to transition its payors and employer groups to alternative network options as a result of a business combination. We anticipate the transition will continue throughout 2012 and will be complete by December 31, 2012, negatively impacting the claims and revenue generated from the account during 2012 and thereafter.

The following table details the change in client accounts for the years ended December 31:

	Net Revenue											Billed Claims Volume
							Change							Change
(in thousands)	2011			2010			$			%		2011	2010	Claims		%
Client A	$	16,584		$	29,587		$	(13,003	)	(44	)%	75	124	(49	)	(40	)%
Client B	9,959			16,715			(6,756		)	(40	)	43	91	(48	)	(53	)
All other legacy clients	10,101			9,695			406			4		68	86	(18	)	(21	)
Clients implemented in 2010	11,901			5,899			6,002			102		61	28	33		118
Clients implemented in 2011	983			—			983			nm		6	—	6		nm
Provision for refunds	(622		)	(695		)	73			nm		—	—	—		nm
Total	$	48,906		$	61,201		$	(12,295	)	(20	)%	253	329	(76	)	(23	)%

The Company is seeking growth by aggressively pursuing middle-market insurance companies, TPAs and direct payors. The Company continues to derive a significant amount of its revenues from its traditional PPO relationships, but we have shifted our focus and now aggressively target TPAs and direct payors. During 2011, revenue from TPAs, insurance companies and direct payors increased 31%, as compared to 2010. In addition, revenue from those clients was approximately 45% of total revenue, compared to 27% in 2010. A portion of our target market is Employee Retirement Income Security Act ("ERISA")-based health plans that seek cost-effective healthcare benefits for its members and present an opportunity for the Company to influence plan design and provide incentives.

20

The following table details the change in revenue generated from different client groups for the years ended December 31:

	2011					2010					Change
($ in thousands)	Count	Revenue		% of revenue		Count	Revenue		% of revenue		$			%
PPOs	11	$	27,367	55.3	%	11	$	44,970	72.7	%	$	(17,603	)	(39	)%
TPAs	24	16,003		32.3		20	10,601		17.1		5,402			51
Direct/Insurance Companies	3	6,158		12.4		3	6,325		10.2		(167		)	(3	)
Gross revenue, before provision for refunds		$	49,528	100.0	%		$	61,896	100.0	%	$	(12,368	)	(20	)%

Periodically, we pay refunds to our payors. Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. Our provision for refunds is estimated based on historical data and is presented as an offset to revenue. The provision for the year ended December 31, 2011 was approximately $622,000 compared to approximately $695,000 for the year ended December 31, 2010. We have no direct control over the circumstances creating the need for certain refunds, but we attempt to minimize our exposure through our internal processes and procedures. One such procedure is recouping amounts paid to ancillary service providers on such claims, which offsets our exposure.

Cost of Revenues

Cost of revenues is comprised of payments to our providers, administrative fees paid to our client payors for converting claims to electronic data interchange and routing them to both the Company for processing and to their payors for payment, and the non-variable costs of our claims administration and ancillary service provider development organizations.  Payments to providers is the largest component of our cost of revenues and it consists of our payments for ancillary care services in accordance with contracts negotiated separately with providers for specific ancillary services.  

The following table sets forth a comparison of the key components of our cost of revenues, for the years ended December 31:

									Change
($ in thousands)	2011		% of revenue		2010		% of revenue		$			%
Provider payments	$	37,588	76.9	%	$	45,789	74.8	%	$	(8,201	)	(18	)%
Administrative fees	2,395		4.9		3,317		5.4		(922		)	(28	)
Claims administration and provider development	4,162		8.5		4,645		7.6		(483		)	(10	)
Total cost of revenues	$	44,145	90.3	%	$	53,751	87.8	%	$	(9,606	)	(18	)%

Provider payments.  The 18% decrease in provider payments in 2011 compared to 2010 is consistent with the decline in net revenue, primarily related to our two significant clients.  The increase in provider payments as a percentage of net revenue compared to the prior year is primarily due to the following:

• A shift in mix away from clients that generate higher margins, relative to other clients, primarily as a result of (1) the loss of a large employer group by our most significant client which carried advantageous pricing relative to our other clients, and (2) more competitive pricing associated with our TPA and direct payor clients relative to other clients; and

• A shift in mix from higher margin categories, such as diagnostic imaging services, to lower margin categories, such as dialysis services. In addition, margins on dialysis services claims declined as a result of (1) a shift to service providers with which we have less advantageous pricing, and (2) the mix of demand for certain specialties. Both resulted in pressure on contribution margin.

Administrative fees. Administrative fees paid to clients as a percent of net revenue declined to 4.9% in 2011 compared to 5.4% in 2010. The decrease is due to a change in mix from clients with higher administrative fees to clients with lower administrative fees, primarily clients implemented in 2010.

21

Claims administration and provider development. Our claims administration organization consists of our operations and information technology groups.  Our operations group is responsible for all aspects of the claims management and processing including billing, quality assurance, credentialing new service providers and collections efforts.  Our information technology group is responsible for maintaining and enhancing the technological capabilities and applications with the claims management process.  

Our provider development group is responsible for developing our network of ancillary healthcare service providers, which includes contracting with providers to be included in the network and maintaining a relationship with existing providers, all for the purpose of enhancing our ancillary service provider network offering to our client payors.

The following table details the costs within the claims administration and provider development groups for the periods presented:

	Claims Administration								Provider Development									Total
					Increase								Increase									Increase
($ in thousands)	2011		2010		(Decrease)				2011		2010		(Decrease)					2011		2010		(Decrease)
Total wages, incentives and benefits	$	2,744	$	2,722	$	22	1	%	$	956	$	1,331	$	(375	)	(28	)%	$	3,700	$	4,053	$	(353	)	(9	)%
Other	182		126		56		44	%	280		466		(186		)	(40	)	462		592		(130		)	(22	)
	$	2,926	$	2,848	$	78	3	%	$	1,236	$	1,797	$	(561	)	(31	)%	$	4,162	$	4,645	$	(483	)	(10	)%

The decline in provider development costs are primarily due to changes in headcount. Effective January 1, 2011, the Company strategically realigned personnel within departments based on responsibilities and functionality in order to achieve greater productivity. As a result, five positions were realigned out of the provider development group; three positions serving in a pricing capacity were allocated to the finance group (classified as selling, general and administrative expenses) and two positions that execute the credentialing of new providers and re-credentialing of existing providers were allocated to the operations group.

The following table details the change in average headcount in the groups related to claims administration and provider development for the years ended December 31:

Headcount (average)	2011	2010
Operations	19	20
Information technology	13	14
Total claims administration	32	34
Provider development	9	12

Contribution margin is calculated by dividing the difference between net revenues and total costs of revenues by net revenues. The following table sets forth a comparison of contribution margin percentage for the periods ended December 31:

	2011		2010		Percent Change
Contribution margin	9.7	%	12.2	%	(2.5	)%

 The factors driving the overall decline in contribution margin percentage are discussed in the Cost of Revenues section above. Our contribution margin percentage fluctuates over time due to changes in the prices we charge our client payors as compared to the financial terms of our provider agreements, changes in costs of claims administration and provider development, and changes in the mix of services we provide.  There can be no assurances that we will be able to maintain contribution margin at current levels, either in absolute or in percentage terms.

22

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses consist primarily of salaries and related benefits, travel costs, sales commissions, sales materials, other marketing related expenses, costs of corporate operations, finance and accounting, human resources and other general operating expenses of the Company. The following table sets forth a comparison of our SG&A expenses for the periods presented ending December 31:

					Change
($ in thousands)	2011		2010		$		%
Selling, general and administrative expenses	6,240		6,190		$	50	1	%
Percentage of total net revenues	12.8	%	10.1	%

SG&A expenses in 2011 include approximately $263,000 of severance costs related to the resignation of our former Chief Executive Officer in July 2011.  For the year ended December 31, 2010, SG&A expenses include approximately $143,000 of severance costs related to the departure of our former Chief Financial Officer in March 2010. In addition, three positions were realigned into our finance group as of January 1, 2011. The wages and benefits for those three positions was approximately $200,000 for 2011.

Depreciation and Amortization

The following table sets forth a comparison of depreciation and amortization for the periods ended December 31: 

					Change
($ in thousands)	2011		2010		$		%
Depreciation	$	664	$	639	$	25	4	%
Amortization	128		128		—		—
Total Depreciation and Amortization	$	792	$	767	$	25	3	%

Goodwill Impairment Charge

The Company initiated an interim goodwill impairment analysis as of September 30, 2011. The Company concluded that impairment indicators existed based upon, among other things, the decline in market capitalization, revenue declines of the Company's two most significant client accounts and operating results for the nine months ended September 30, 2011, which required the performance of an interim impairment test. As a result, the Company performed the generally recognized threshold goodwill impairment test (step 1) which indicated that the fair value of the Company (single reporting unit), based primarily on the trading value of the Company's common stock plus an estimated control premium, was less than the book value of its net assets. Therefore, the required next analysis of the assessment was performed (step 2), in which the implied fair value of the Company's goodwill was compared to the book value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination, that is, the estimated fair value of the Company is allocated to all of those assets and liabilities (including both recognized and unrecognized intangible assets) as if the Company had been acquired in a business combination and the estimated fair value was the purchase price paid. If the carrying amount of goodwill is greater than the implied fair value of goodwill, an impairment loss is recognized in the amount of the excess and is charged to operations.

As a result of our preliminary interim impairment assessment, the Company recognized a non-cash goodwill impairment charge of $4.4 million as of September 30, 2011, representing the entire balance of goodwill. The Company subsequently finalized its analysis with no change to the preliminary results. In addition, the Company also reviewed the carrying value of intangible assets, which is limited to our ancillary provider network and property and equipment, to determine if impairment exists. Based on this analysis, the Company concluded that no impairment of the ancillary provider network or property and equipment existed as of September 30, 2011. A deferred tax benefit of $1.5 million was recognized as of September 30, 2011 as a result of the total amount of estimated impairment charges, but a valuation allowance was immediately provided.

The impairment was indicated as a result of the decline in the Company's stock price which the Company believes was caused by the continued declines in revenue and claims volume from the Company's two most significant clients and the expectation of significantly diminishing revenue from at least one of these clients. The impairment did not impact cash flows.

23

Other Income

The following table sets forth a comparison of the components of other income for the periods ended December 31: 

					Change
($ in thousands)	2011		2010		$			%
Interest income	$	39	$	86	$	(47	)	(55	)%
Unrealized gain on warrant derivative	—		18		(18		)	(100	)
Total other income	$	39	$	104	$	(65	)	(63	)%

Income Tax Provision

For the years ended December 31, 2011 and 2010, we recorded an income tax provision of approximately $644,000 and $111,000, respectively.  The effective income tax rate for 2011 was different from the statutory United States federal income tax rate of 34% due to the establishment of a deferred income tax valuation allowance of approximately $2.8 million.

Liquidity and Capital Resources

As of December 31, 2011, the Company had a working capital surplus of $11.3 million compared to $12.6 million at December 31, 2010.  In addition, our cash and cash equivalents balance decreased to $11.3 million as of December 31, 2011 compared to $14.5 million at December 31, 2010.  Following are the components of our cash flows for the year ended December 31, 2011:

Operating Activities. For the year ended December 31, 2011, the Company had cash outflows from operating activities of approximately $2.5 million.  The outflows were primarily the result of the timing of payments made to providers.

Investing Activities. For the year ended December 31, 2011, the Company had cash outflows from investing activities of approximately $669,000, which was comprised mainly of approximately $611,000 of internal software development costs. The development related to projects to enhance our internal repricing and billing system.

Financing Activities. The Company had cash outflows from financing activities of approximately $57,000 during the year ended December 31, 2011 related to the payment of income tax withholdings on net exercises of equity incentives.

Overall, the $3.2 million decline in our cash and cash equivalents during 2011 was due to the timing of cash receipts and payments to providers and operating losses. Payments were made to providers in the first quarter of 2011 related to above average cash receipts/collections from client payors in the fourth quarter of 2010. The Company's cash and cash equivalents declined only $672,000 during the period between September 30, 2010 and December 31, 2011.

In light of our declining revenues and the impact on cash flows during 2011, we attempted to maintain, and where appropriate reduce, our non-variable costs for the primary purpose of maintaining our current cash reserves. In 2011, our non-variable costs (claims administration, provider development and selling, general and administrative expenses) declined 5%, from $10.7 million in 2010, to $10.1 million, excluding the impact of severance charges. We will continue to monitor our cash position and if necessary will strategically eliminate non-variable cash outflows. Historically, we have relied on external sources of capital, including indebtedness or issuance of equity securities, and during the past three years, earnings, to fund our operations. We believe our current cash balance of $11.3 million as of December 31, 2011 and expected future cash flows from operations will be sufficient to meet our anticipated cash needs for working capital, capital expenditures and other activities through at least the next twelve months.  If operating cash flows are not sufficient to meet our needs, we believe that credit or access to capital through issuance of equity would be available to us. However, as a result of the tightening in the credit markets, low level of liquidity in many financial markets and extreme volatility in fixed income, credit, currency and equity markets, there cannot be assurances that, if necessary, we would be successful in obtaining sufficient capital financing on commercially reasonable terms or at all.  We do not have any lines of credit, credit facilities or outstanding bank indebtedness as of December 31, 2011.

Inflation

Inflation did not have a significant impact on the Company’s costs during the years ended December 31, 2011 and December 31, 2010, respectively.  The Company continues to monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions.

24

Off-Balance Sheet Arrangements

The Company did not have any off-balance sheet arrangements at December 31, 2011 or December 31, 2010 or for the periods then ended.

Critical Accounting Policies

Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.

The Company’s significant accounting policies are described in the Notes to the Consolidated Financial Statements located elsewhere in this Annual Report on Form 10-K. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, the following accounting policies are deemed to be critical by our management:

Goodwill.

The 2003 acquisition of the assets of our predecessor, American CareSource Corporation by Patient Infosystems (now CareGuide, Inc.), our former parent corporation resulted in the creation of goodwill.  Purchase price in excess of that allocated to identifiable tangible and intangible assets (based on estimated fair values), was allocated to goodwill. The goodwill evaluation for impairment is performed annually as of December, or more frequently if impairment indicators arise. We perform a two-step impairment test on goodwill. In the first step, we compare the fair value of the Company (single reporting unit) to its book value. If the fair value exceeds the book value of the net assets, goodwill is not considered impaired and we are not required to perform further testing. If the book value of the net assets exceeds the fair value, then we must perform the second step of the impairment test in order to determine the implied fair value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination, that is, the estimated fair value of the Company is allocated to all of those assets and liabilities (including both recognized and unrecognized intangible assets) as if the Company has been acquired in a business combination and the estimated fair value was the purchase price paid. If the book value of goodwill is greater than implied fair value of goodwill, an impairment loss is recognized in the amount of the excess and is charged to operations. Based on indicators such as the decline in market capitalization and revenue declines of the Company's two most significant client accounts, the annual goodwill impairment analysis was performed during the third quarter of 2011 and resulted in a goodwill impairment charge of $4.4 million, representing the entire balance of goodwill.

Intangible Assets.

Intangible assets consist of ancillary provider network and internally developed claims payment and billing software.  The software has been fully amortized using the straight-line method over its expected useful life of 5 years. The ancillary provider network is being amortized using the straight-line method over its expected useful life of 15 years.  Our experience to date is that we have approximately 2-5% annual turnover or attrition of provider contracts.  The provider contracts are being accounted for on a pooled basis and the actual cancellation rates of provider contracts that were acquired will be monitored for potential impairment or amortization adjustment, if warranted.  As of December 31, 2011, there is no impairment of this intangible asset.  The cost of adding additional providers is considered an ongoing operating expense.

25

Deferred Income Taxes.

Income taxes are accounted for under the asset and liability method.  Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as “temporary differences”.  The Company records the tax effect of these temporary differences as “deferred tax assets” (generally items that can be used as a tax deduction or credit in the future periods) and “deferred tax liabilities” (generally items that we received a tax deduction for, which have not yet been recorded in the statement of operations).  The deferred tax assets and liabilities are measured using enacted tax rules and laws that are expected to be in effect when the temporary differences are expected to be recovered or settled.  The realization of the deferred tax assets, including net operating loss carryforwards, is subject to our ability to generate sufficient taxable income during the periods in which the temporary differences become realizable. In evaluating whether a valuation allowance is required, we consider all available positive and negative evidence, including prior operating results, the nature and reason of any losses, our forecast of future taxable income, and the dates of which any deferred tax assets are expected to expire. These assumptions require a significant amount of judgment, including estimates of future taxable income. The estimates are based on our best judgment at the time made based on current and projected circumstances and conditions. Based on estimates impacted by such factors as revenue declines of our two most significant client accounts and the impact of operating results, we determined that a valuation allowance was appropriate. A valuation allowance in the amount of $2.8 million was established against the net deferred tax assets with the exception of the Texas tax credit carryforward of approximately $232,000.

Revenue recognition.

The Company recognizes revenue on the services that it provides, which includes (i) providing payor clients with a comprehensive network of ancillary healthcare providers, (ii) providing claims management, reporting, processing and payment services, (iii) providing network/need analysis to assess the benefits to payor clients of adding what additional/different service providers to the client-specific provider networks and (iv) providing credentialing of network services providers for inclusion in the client payor-specific provider networks.  Revenue is recognized when services are delivered, which occurs after processed claims are billed to the client payors and collections are reasonably assured.  The Company estimates revenues and costs of revenues using average historical collection rates and average historical margins earned on claims.  Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected.

The Company determines whether it is acting as a principal or agent in the fulfillment of the services rendered.  After careful evaluation of the key gross and net revenue recognition indicators, the Company acknowledges that while the determination of gross versus net reporting is highly judgmental in nature, the Company has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

Following are the key indicators that support the Company’s conclusion that it acts as a principal when settling claims for service providers through its contracted service provider network:

• The Company is the primary obligor in the arrangement.  The Company has assessed its role as primary obligor as a strong indicator of gross reporting.  The Company believes that it is the primary obligor in its transactions because it is responsible for providing the services desired by its client payors.  The Company has distinct, separately negotiated contractual relationships with its client payors and with the ancillary health care providers in its networks.  The Company does not negotiate “on behalf of” its client payors and does not hold itself out as the agent of the client payors when negotiating the terms of the Company’s ancillary healthcare service provider agreements.  The Company’s agreements contractually prohibit client payors and service providers to enter into direct contractual relationships with one another.  The client payors have no control over the terms of the Company’s agreements with the service providers.  In executing transactions, the Company assumes key performance-related risks.  The client payors hold the Company responsible for fulfillment, as the provider, of all of the services the client payors are entitled to under their contracts; client payors do not look to the service providers for fulfillment.  In addition, the Company bears the pricing/margin risk as the principal in the transactions.  Because the contracts with the client payors and service providers are separately negotiated, the Company has complete discretion in negotiating both the prices it charges its client payors and the financial terms of its agreements with the service providers.  Since the Company’s profit is the spread between the amounts received from the client payors and the amount paid to the service providers, it bears significant pricing/margin risk.  There is no guaranteed mark-up payable to the Company on the amount the Company has contracted.  Thus, the Company bears the risk that amounts paid to the service provider will be greater than the amounts received from the client payors, resulting in a loss or negative claim.

26

• The Company has latitude in establishing pricing.  As stated above, the Company has complete latitude in negotiating the price to be paid to the Company by each client payor and the price to be paid to each contracted service provider.  This type of pricing latitude indicates that the Company has the risks and rewards normally attributed to a principal in the transactions.

• The Company changes the product or performs part of the services.  The Company provides the benefits associated with the relationships it builds with the client payors and the services providers.  While the parties could deal with each other directly, the client payors would not have the benefit of the Company’s experience and expertise in assembling a comprehensive network of service providers, in claims management, reporting and processing and payment services, in performing network/needs analysis to assess the benefits to client payors of adding additional/different service providers to the client payor-specific provider networks, and in credentialing network service providers.

• The Company has complete discretion in supplier selection.   One of the key factors considered by client payors who engage the Company is to have the Company undertake the responsibility for identifying, qualifying, contracting with and managing the relationships with the ancillary healthcare service providers.  As part of the contractual arrangement between the Company and its client payors, the payors identify their obligations to their respective covered persons and then work with the Company to determine the types of ancillary healthcare services required in order for the payors to meet their obligations.  The Company may select the providers and contract with them to provide services at its discretion.

• The Company is involved in the determination of product or service specifications.  The Company works with its client payors to determine the types of ancillary healthcare services required in order for the payors to meet their obligations to their respective covered persons.  In some respects, the Company is customizing the product through its efforts and ability to assemble a comprehensive network of providers for its payors that is tailored to each payor’s specific needs.  In addition, as part of its claims processing and payment services, the Company works with the client payors, on the one hand, and the providers, on the other, to set claims review, management and payment specifications.

• The supplier (and not the Company) has credit risk.  The Company believes it has some level of credit risk, but that risk is mitigated because the Company does not remit payment to providers unless and until it has received payment from the relevant client payors following the Company’s processing of a claim.

• The amount that the Company earns is not fixed.  The Company does not earn a fixed amount per transaction nor does it realize a per-person per-month charge for its services.

The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company has general inventory risk.  The Company does not have any general inventory risk, as its business is not related to the manufacture, purchase or delivery of goods and it does not purchase in advance any of the services to be provided by the ancillary healthcare service providers.  While the absence of this risk would be one indicator in support of net revenue reporting, as described in detail above, the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

The Company records a provision for refunds on a periodic basis. Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. In some instances, we will recoup payment made to the ancillary service provider if the claim has been fully resolved. An evaluation is performed periodically and is based on historical data. We present revenue net of the provision for refunds on the consolidated statement of operations.

Pending Accounting Pronouncements

None.

Item 8.                    Financial Statement and Supplementary Data.

The Company’s financial statement and supplementary data required to be filed pursuant to this Item 8 are located at the end of this Annual Report on Form 10-K, beginning on page F-1.

Item 9.                    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

27

Item 9A.                    Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2011.  Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act) are effective to ensure that information required to the disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

Management’s Annual Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting by the Company.  “Internal control over financial reporting“ is defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act, as amended, as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the Company’s Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

• Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

• Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the Company; and

• Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Internal control over financial reporting has inherent limitations and may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2011. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – IntegratedFramework. Management reviewed the results of its assessment with the Audit Committee of the Company’s Board of Directors.  Based on this assessment, management believes that, as of December 31, 2011, the Company has maintained effective internal control over financial reporting.

This Annual Report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting.  Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report.

Changes in Internal Control over Financial Reporting

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has concluded there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company's last fiscal quarter that have materially affected the Company’s internal controls over financial reporting or are reasonably likely to materially affect internal controls over financial reporting, including any corrective actions with regard to significant deficiencies and material weaknesses.

Item 9B.                    Other Information

Not applicable

28

PART III

Item 10.                  Directors, Executive Officers and Corporate Governance

The information required by this Item 10 is incorporated herein by reference to the applicable information contained in the definitive proxy statement for our 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, which will be filed with the SEC not later than 120 days after the Company’s fiscal year ended December 31, 2011.

Item 11.                    Executive Compensation

The information required by this Item 11 is incorporated herein by reference to the applicable information contained in the definitive proxy statement for our 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, which will be filed with the SEC not later than 120 days after the Company’s fiscal year ended December 31, 2011.

Item 12.                    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table provides information with respect to the equity securities that are authorized for issuance under our equity compensation plans as of December 31, 2011:

Equity Compensation Plan Information at December 31, 2011
Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (Column (a))	Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plans, excluding securities reflected in column (a)
Equity compensation plans approved by security holders	2,236,357	$	2.22	1,640,869
Equity compensation plans not approved by security holders	—	—		—
Total	2,236,357	$	2.22	1,640,869

In addition, warrants to purchase 475,000 shares of Common Stock of the Company were issued and outstanding as of December 31, 2011, as shown in the table below.  

	Shares of Common Stock issuable under outstanding warrants	Weighted-average exercise price of outstanding warrants
Series D (1)	225,000	$	1.84
Series E (2)	250,000	$	1.67
Total Warrants Outstanding	475,000	$	1.75

(1) These warrants were granted on May 21, 2007 to Corporate Health Plans of America, Inc., an affiliate of the Company’s client, Texas True Choice, Inc. (“Texas True Choice”), as partial compensation to Texas True Choice for services to be performed by it pursuant to an ancillary care services network access agreement between the Company and Texas True Choice. 

(2) These warrants were granted to an employee on February 25, 2011 as incentive to achieve defined and agreed upon revenue targets generated by new clients within a five year term. The Company agreed to issue warrants to purchase 250,000 shares of common stock with an exercise price of $1.67. The agreement also obligates the Company to issue warrants to purchase up to an additional 500,000 shares of common stock (issued in 250,000 increments) upon the achievement of additional defined agreed upon revenue targets. On February 1, 2012, certain terms of the agreement were modified, including the revenue targets and the total number of shares under the initial and future warrants. The warrant issuance now allows for 133,334 shares to be purchased at an exercise price of $0.50, 66,667 of which are vested, and the remaining 66,667 shares vesting upon the achievement of certain revenue targets. The number of shares under the future warrant issuances was also reduced to 266,666 (issued in 133,333 increments) shares based upon the achievement of additional defined agreed upon revenue targets. In making the issuance of these warrants without registration under the Securities Act of 1933, as amended (the "Securities Act"), the Company relied upon the exemption from registration contained in Section 4(2) of the Securities Act.

29

The other information required by this Item 12 is incorporated herein by reference to the applicable information contained in the definitive proxy statement for our 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, which will be filed with the SEC not later than 120 days after the Company’s fiscal year ended December 31, 2011.

Item 13.                    Certain Relationships and Related Transactions, and Director Independence

The information required by this Item 13 is incorporated herein by reference to the applicable information contained in the definitive proxy statement for our 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, which will be filed with the SEC not later than 120 days after the Company’s fiscal year ended December 31, 2011.

Item 14.                    Principal Accounting Fees and Services

The information required by this Item 14 is incorporated herein by reference to the applicable information contained in the definitive proxy statement for our 2012 annual meeting of stockholders or the Registrant's annual report on Form 10-K/A, which will be filed with the SEC not later than 120 days after the Company’s fiscal year ended December 31, 2011.

30

PART IV

Item 15.                  Exhibits and Financial Statement Schedules

(a)    The following documents are filed as part of this Annual Report on Form 10-K:

(1)    Financial Statements

The following financial statements are set forth in Item 8 hereof:

Document	Pages
Report of Independent Registered Public Accounting Firm	F-1
Consolidated Statements of Operations for the Years Ended December 31, 2011 and 2010	F-2
Consolidated Balance Sheets as of December 31, 2011 and 2010	F-3
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2011 and 2010	F-4
Consolidated Statements of Cash Flows for the Years Ended December 31, 2011 and 2010	F-5
Notes to Consolidated Financial Statements	F-6

(2)    Financial Statement Schedules    

None.

(3)    Exhibits 

Reference is made to the Exhibit Index at the end of this Annual Report on Form 10-K.

31

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders

American CareSource Holdings, Inc.

We have audited the accompanying consolidated balance sheets of American CareSource Holdings, Inc. and Subsidiary as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended.  These financial statements are the responsibility of the Company’s management.  Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of American CareSource Holdings, Inc. and Subsidiary as of December 31, 2011 and 2010, and the results of their operations and their cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

/s/ McGladrey & Pullen, LLP

Des Moines, Iowa

March 9, 2012

F-1

AMERICAN CARESOURCE HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

For the years ended December 31

(amounts in thousands, except per share data)

	2011			2010
Net revenues	$	48,906		$	61,201
Cost of revenues:
Provider payments	37,588			45,789
Administrative fees	2,395			3,317
Claims administration and provider development	4,162			4,645
Total cost of revenues	44,145			53,751
Contribution margin	4,761			7,450
Selling, general and administrative expenses	6,240			6,190
Depreciation and amortization	792			767
Goodwill impairment charge	4,361			—
Total operating expenses	11,393			6,957
Operating income (loss)	(6,632		)	493
Other income	39			104
Income (loss) before income taxes	(6,593		)	597
Income tax provision	644			111
Net income (loss)	$	(7,237	)	$	486
Earnings (loss) per common share:
Basic	$	(0.43	)	$	0.03
Diluted	$	(0.43	)	$	0.03
Basic weighted average common shares outstanding	17,005			16,550
Diluted weighted average common shares outstanding	17,005			17,176

See accompanying notes.

F-2

AMERICAN CARESOURCE HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

December 31

(amounts in thousands except per share amounts)

	2011			2010
ASSETS
Current assets:
Cash and cash equivalents	$	11,315		$	14,512
Accounts receivable, net	4,317			5,510
Prepaid expenses and other current assets	559			532
Deferred income taxes	6			237
Total current assets	16,197			20,791
Property and equipment, net	1,829			1,824
Other assets:
Deferred income taxes	226			609
Other assets	16			340
Intangible assets, net	896			1,025
Goodwill	—			4,361
	$	19,164		$	28,950
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Due to service providers	$	3,678		$	6,718
Accounts payable and accrued liabilities	1,237			1,446
Total current liabilities	4,915			8,164
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized none issued	—			—
Common stock, $0.01 par value; 40,000 shares authorized; 17,076 and 16,922 shares issued and outstanding in 2011 and 2010, respectively	171			169
Additional paid-in capital	22,300			21,602
Accumulated deficit	(8,222		)	(985		)
Total stockholders’ equity	14,249			20,786
	$	19,164		$	28,950

See accompanying notes.

F-3

AMERICAN CARESOURCE HOLDINGS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

For the years ended December 31, 2011 and 2010

(amounts in thousands)

	Common Stock
	Shares	Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Equity
Balance at December 31, 2009	15,642	$	156	$	20,605		$	(1,471	)	$	19,290
Net income	—	—		—			486			486
Stock-based compensation expense	—	—		871			—			871
Issuance of common stock upon exercise of restricted stock units, net of tax withholdings	23	1		(19		)	—			(18		)
Issuance of common stock upon exercise of stock warrants	1,257	12		145			—			157
Balance at December 31, 2010	16,922	$	169	$	21,602		$	(985	)	$	20,786
Net loss	—	—		—			(7,237		)	(7,237		)
Stock-based compensation expense	—	—		738			—			738
Issuance of common stock upon exercise of options and issuance of restricted stock units, net of tax withholdings	154	2		(40		)	—			(38		)
Balance at December 31, 2011	17,076	$	171	$	22,300		$	(8,222	)	$	14,249

See accompanying notes.

F-4

AMERICAN CARESOURCE HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the years ended December 31

(amounts in thousands)

	2011			2010
Cash flows from operating activities:
Net income (loss)	$	(7,237	)	$	486
Adjustments to reconcile net income (loss) to net cash provided (used) by operations:
Stock-based compensation expense	738			871
Depreciation and amortization	792			767
Goodwill impairment charge	4,361			—
Unrealized gain on warrant derivative	—			(18		)
Amortization of long-term client agreement	250			250
Client administration fee expense related to warrants	67			200
Deferred income taxes	614			47
Changes in operating assets and liabilities:
Accounts receivable	1,193			1,845
Prepaid expenses and other assets	(21		)	157
Accounts payable and accrued liabilities	(188		)	(432		)
Due to service providers	(3,040		)	(984		)
Net cash provided by (used in) operating activities	(2,471		)	3,189
Cash flows from investing activities:
Investments in software development costs	(611		)	(402		)
Additions to property and equipment	(58		)	(300		)
Net cash (used in) investing activities	(669		)	(702		)
Cash flows from financing activities:
Proceeds from exercise of equity warrants	—			157
Payment of income tax withholdings on net exercise of equity incentives	(57		)	—
Net cash provided by (used in) financing activities	(57		)	157
Net increase (decrease) in cash and cash equivalents	(3,197		)	2,644
Cash and cash equivalents at beginning of period	14,512			11,868
Cash and cash equivalents at end of period	$	11,315		$	14,512
Supplemental cash flow information:
Cash paid for taxes, net of refunds received	$	52		$	103
Supplemental non-cash financing activity:
Income tax withholdings on exercise of equity incentives	$	—		$	19

See accompanying notes.

F-5

AMERICAN CARESOURCE HOLDINGS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2011

(Tables in thousands, except per share amounts)

1. Summary of Significant Accounting Policies

American CareSource Holdings, Inc. (“ACS,” “Company,”  the “Registrant,” “we,” “us,” or “our”) is an ancillary services company that offers cost effective access to a comprehensive national network of ancillary healthcare service providers.  The Company sells its services to a number of healthcare companies including preferred provider organizations ("PPOs"), third party administrators (“TPAs”), insurance companies, large self-funded organizations and various employee groups.  The Company offers payors this solution by:

• lowering its payors’ ancillary care costs throughout our network of high quality, cost effective providers that the Company has under contract at more favorable terms than they could generally obtain on their own; generally we provide our payor clients with 8-12% incremental savings on their ancillary healthcare services expenditures;

• providing payors with a comprehensive network of ancillary healthcare services providers that is tailored to each payor’s specific needs and is available to each payor’s covered persons for covered services;

• providing payors with claims management, reporting and processing and payment services;

• performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor -specific provider networks; and

• credentialing network service providers for inclusion in the payor -specific provider networks.  

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its one wholly-owned subsidiary, Ancillary Care Services, Inc.  All material intercompany accounts and transactions are eliminated in consolidation.  

Cash and Cash Equivalents

The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents include amounts in deposit accounts in excess of federally insured limits of $250,000.  The Company has not experienced any losses in such accounts.

Revenue Recognition

The Company recognizes revenue on the services that it provides, which includes (i) providing payor clients with a comprehensive network of ancillary healthcare providers, (ii) providing claims management, reporting, processing and payment services, (iii) providing network/need analysis to assess the benefits to payor clients of adding additional/different service providers to the client-specific provider networks and (iv) providing credentialing of network services providers for inclusion in the client payor-specific provider networks.  Revenue is recognized when services are delivered, which occurs after processed claims are billed to the client payors and collections are reasonably assured.  The Company estimates revenues and costs of revenues using average historical collection rates and average historical margins earned on claims.  Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected.

The Company determines whether it is acting as a principal or agent in the fulfillment of the services rendered.  After careful evaluation of the key gross and net revenue recognition indicators, the Company acknowledges that while the determination of gross versus net reporting is highly judgmental in nature, the Company has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

Following are the key indicators that support the Company’s conclusion that it acts as a principal when settling claims for service providers through its contracted service provider network:

• The Company is the primary obligor in the arrangement.  The Company has assessed its role as primary obligor as a strong indicator of gross reporting.  The Company believes that it is the primary obligor in its transactions because it is responsible for providing the services desired by its client payors.  The Company has distinct, separately negotiated contractual relationships with its client payors and with the ancillary health care providers in its networks.  The Company does not negotiate “on behalf of” its client payors and does not hold itself out as the agent of the client payors when negotiating the terms of the Company’s ancillary healthcare service provider agreements.  The Company’s agreements contractually prohibit client payors and service providers to enter into direct contractual relationships with one another.  The client payors have no control over the terms of the Company’s agreements with the service providers.  In executing transactions, the Company assumes key performance-related risks.  The client payors hold the Company responsible for fulfillment, as the provider, of all of the services the client payors are entitled to under their contracts; client payors do not look to the service providers for fulfillment.  In addition, the Company bears the pricing/margin risk as the principal in the transactions.  Because the contracts with the client payors and service providers are separately negotiated, the Company has complete discretion in negotiating both the prices it charges its client payors and the financial terms of its agreements with the service providers.  Since the Company’s profit is the spread between the amounts received from the client payors and the amount paid to the service providers, it bears significant pricing/margin risk.  There is no guaranteed mark-up payable to the Company on the amount the Company has contracted.  Thus, the Company bears the risk that amounts paid to the service provider will be greater than the amounts received from the client payors, resulting in a loss or negative claim.

• The Company has latitude in establishing pricing.  As stated above, the Company has complete latitude in negotiating the price to be paid to the Company by each client payor and the price to be paid to each contracted service provider.  This type of pricing latitude indicates that the Company has the risks and rewards normally attributed to a principal in the transactions.

• The Company changes the product or performs part of the services.  The Company provides the benefits associated with the relationships it builds with the client payors and the services providers.  While the parties could deal with each other directly, the client payors would not have the benefit of the Company’s experience and expertise in assembling a comprehensive network of service providers, in claims management, reporting and processing and payment services, in performing network/needs analysis to assess the benefits to client payors of adding additional/different service providers to the client payor-specific provider networks, and in credentialing network service providers.

• The Company has discretion in supplier selection.  The Company has complete discretion in supplier selection.  One of the key factors considered by client payors who engage the Company is to have the Company undertake the responsibility for identifying, qualifying, contracting with and managing the relationships with the ancillary healthcare service providers.  As part of the contractual arrangement between the Company and its client payors, the payors identify their obligations to their respective covered persons and then work with the Company to determine the types of ancillary healthcare services required in order for the payors to meet their obligations.  The Company may select the providers and contract with them to provide services at its discretion.

• The Company is involved in the determination of product or service specifications.  The Company works with its client payors to determine the types of ancillary healthcare services required in order for the payors to meet their obligations to their respective covered persons.  In some respects, the Company is customizing the product through its efforts and ability to assemble a comprehensive network of providers for its payors that is tailored to each payor’s specific needs.  In addition, as part of its claims processing and payment services, the Company works with the client payors, on the one hand, and the providers, on the other, to set claims review, management and payment specifications.

• The supplier (and not the Company) has credit risk.  The Company believes it has some level of credit risk, but that risk is mitigated because the Company does not remit payment to providers unless and until it has received payment from the relevant client payors following the Company’s processing of a claim.

• The amount that the Company earns is not fixed.  The Company does not earn a fixed amount per transaction nor does it realize a per-person per-month charge for its services.

The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company has general inventory risk.  The Company does not have any general inventory risk, as its business is not related to the manufacture, purchase or delivery of goods and it does not purchase in advance any of the services to be provided by the ancillary healthcare service providers.  While the absence of this risk would be one indicator in support of net revenue reporting, as described in detail above, the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

If the Company were to report its revenues net of provider payments rather than on a gross reporting basis, for the years ended December 31, 2011 and December 31, 2010, its net revenues would have been $11.3 million and $15.4 million, respectively.

The Company records a provision for refunds based on an estimate of historical refund amounts. Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. In some instances, we will recoup payments made to the ancillary service provider if the claim has been fully resolved. The evaluation is performed periodically and is based on historical data. We present revenue net of the provision for refunds on the consolidated statement of operations.

Provider Payments

Payments to providers is the largest component of our cost of revenues and it consists of our payments for ancillary care services in accordance with contracts negotiated separately with providers for specific ancillary services.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual amounts could differ from those estimates.

Property and Equipment

Property and equipment are recorded at original cost and increased by the cost of any significant improvements subsequent to purchase.  The Company expenses repairs and maintenance as incurred.  Depreciation and amortization is calculated using the straight-line method over the shorter of the asset’s estimated useful life or the term of the lease in the case of leasehold improvements.  The Company capitalizes costs associated with software developed for internal use.  During 2011 and 2010, we capitalized approximately $611,000 and $402,000 of internally developed software costs, respectively.  

Research and Development

Research and development costs are expensed as incurred.

Income Taxes

Income taxes are accounted for under the asset and liability method.  Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as “temporary differences”.  The Company records the tax effect of these temporary differences as “deferred tax assets” (generally items that can be used as a tax deduction or credit in the future periods) and “deferred tax liabilities” (generally items that we received a tax deduction for, which have not yet been recorded in the statement of operations).  The deferred tax assets and liabilities are measured using enacted tax rules and laws that are expected to be in effect when the temporary differences are expected to be recovered or settled.  A valuation allowance is established to reduce deferred tax assets considered to be more likely than not that the deferred tax assets will not be realized.

Stock Compensation

The Company records all stock-based payments to employees in the consolidated financial statements based on their estimated fair values as of the measurement date of the respective awards.  Additional information about the Company’s stock-based payment plan is presented in Note 8.

Segment and Related Information

The Company uses the “management approach” for reporting information about segments in our annual and interim financial statements.  The management approach is based on the way the chief operating decision-maker organizes segments within a company for making operating decisions and assessing performance.  Reportable segments are based on products and services, geography, legal structure, management structure and any other manner in which management disaggregates a company.  Based on the “management approach” model, the Company determined that our business is comprised of a single operating segment.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.  The fair value of instruments is determined by reference to various market data and other valuation techniques, as appropriate.  Unless otherwise disclosed, the fair value of short-term financial instruments approximates their recorded values due to the short-term nature of the instruments. 

2. Concentration of Credit Risk

The Company has two client payor relationships that individually comprise a significant portion of our net revenue.  The following is a summary of the approximate amounts of the Company’s net revenue and accounts receivable contributed by each of these clients as of and for the years ended December 31:

	2011								2010
	Accounts Receivable			Revenue			% of Total Revenue		Accounts Receivable			Revenue			% of Total Revenue
Client A	$	1,689		$	16,584		34	%	$	2,448		$	29,587		48	%
Client B	853			9,959			20		1,399			16,715			27
All other legacy clients	1,103			10,101			21		716			9,695			16
Clients implemented in 2010	854			11,901			24		1,310			5,899			10
Clients implemented in 2011	55			983			2		—			—			nm
Allowance for Uncollectable Receivables/Provision for Refunds	(237		)	(622		)	(1	)	(363		)	(695		)	(1	)
	$	4,317		$	48,906		100	%	$	5,510		$	61,201		100	%

Client A includes five entities and Client B includes two entities, which are aggregated for this presentation.  

3. Allowance for Uncollectable Receivables and Refunds

The Company maintains an allowance for uncollectable receivables which primarily relates to payor refunds.  Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. In some instances, we will recoup payment made to the ancillary service provider if the claim has been fully resolved. Co-payments, deductibles and co-insurance payments can also impact the collectability of claims.  While the Company is able to process a claim and estimate the cash it will receive from the payor for that claim, the presence of co-pays, deductibles and co-insurance payments can affect the ultimate collectability of the claim.  The Company records an allowance against revenue to better estimate collectability.   Provisions for refunds recorded, net against revenue, were approximately $622,000 and $695,000 for the years ended December 31, 2011 and 2010, respectively. The allowance was approximately $237,000 and $363,000 for the years ended December 31, 2011 and 2010, respectively.

F-6

4. Property and Equipment

Property and equipment, net consists of the following:

	Useful Lives (years)	2011			2010
Software – internally developed	5	$	2,177		$	1,566
Software – purchased	3-5	592			576
Computer equipment	3-5	507			465
Furniture and fixtures	5	356			356
Leasehold improvements	7	205			205
		3,837			3,168
Accumulated depreciation and amortization		(2,008		)	(1,344		)
Property and equipment, net		$	1,829		$	1,824

The Company recognized depreciation expense of approximately $664,000 and $639,000 during 2011 and 2010, respectively. The depreciation amounts include approximately $330,000 and $260,000 of amortization of internally developed software during 2011 and 2010, respectively.

The Company capitalizes costs associated with internally developed software, developed for internal use only, during the application development stage. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. Costs of significant upgrades and enhancements that result in additional functionality also are capitalized, whereas costs incurred for maintenance and minor upgrades and enhancements are expensed as incurred. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose.

During the years ended December 31, 2011 and December 31, 2010, the Company capitalized costs related to enhancements to its internal information technology claims management applications. The applications were originally developed in 2005 and from time to time, the Company will enhance the functionality and reporting capabilities of the applications. The enhancements are typically developed by the Company's internal information technology group. Periodically, third-party consultants will be utilized to perform the development. For internal resources, the Company capitalizes salary and related benefits, while it capitalizes the cost of external consultants.

5. Income Taxes

Income tax provision for the years ended December 31 differed from the U.S. federal income tax rate of 34% approximately in the amounts indicated as a result of the following:

	2011			2010
Computed “expected” tax provision	$	(2,242	)	$	203
Increase in the valuation allowance for deferred tax assets	2,752			—
State taxes	25			54
Short-fall on stock options and RSUs	145			—
Change in fair value of warrant derivative liability	—			(6		)
Return to provision adjustment	—			(167		)
Other	(36		)	27
Total income tax provision	$	644		$	111

F-7

Differences between financial accounting principles and tax laws cause differences between the bases of certain assets and liabilities for financial reporting purposes and tax purposes.

The tax effects of these differences, to the extent they are temporary, are recorded as deferred tax assets and liabilities and consisted of the following components:

	2011			2010
Deferred tax assets:
Operating loss carryforward	$	872		$	101
Accounts receivable allowance	72			69
Warrants	202			179
Texas tax credit carryforward	232			238
Stock option compensation	1,206			1,140
Goodwill	843			—
Accrued expenses	195			203
Alternative Minimum Tax credit carryforwards	16			16
Total deferred tax assets	3,638			1,946
Deferred tax liabilities:
Goodwill	—			(563		)
Property and equipment	(570		)	(496		)
Prepaid expense	(84		)	(41		)
Total deferred tax liabilities	(654		)	(1,100		)
Valuation allowance	(2,752		)	—
Net deferred tax assets	$	232		$	846

During the year ended December 31, 2011, the Company recognized a valuation allowance of approximately $2.8 million, which was included in the income tax provision for the year ended December 31, 2011. Due to the nature and timing of the reversal of the deferred tax assets and liabilities, the valuation allowance was established against the net deferred tax assets with the exception of the Texas tax credit carryforward of approximately $232,000.

As of December 31, 2011 and 2010, the net operating loss carryforwards were approximately $7.9 million and $5.7 million, which expire in 2025 through 2031. Included in the net operating loss carryforward is approximately $5.4 million which related to the excess tax benefits for stock options and warrants exercised which will result in a credit to additional paid in capital of approximately $1.9 million when the associated tax deduction results in a reduction in the income taxes payable.

The income tax provision shown on the statement of operations for the years ended December 31, 2011 and 2010 consisted of the following:

	2011		2010
Current	$	30	$	64
Deferred	614		47
	$	644	$	111

The Company has evaluated the accounting guidance for uncertainty in income taxes. Management has evaluated their material tax positions and determined no income tax effects with respect to the financial statements. The Company has identified the United States and Texas as major tax jurisdictions and is no longer subject to federal or state income tax examinations by tax authorities for years before 2007. The Company is currently undergoing an examination by tax authorities for its U.S. federal return for the year ended 2009.

F-8

6. Goodwill Impairment and Intangible Assets

Goodwill

The Company initiated an interim goodwill impairment analysis as of September 30, 2011. The Company concluded that impairment indicators existed based upon, among other things, the decline in market capitalization, revenue declines of the Company's two most significant client accounts and operating results for the nine months ended September 30, 2011, which required the performance of an interim impairment test. As a result, the Company performed the generally recognized threshold goodwill impairment test (step 1) which indicated that the fair value of the Company (single reporting unit), based primarily on the trading value of the Company's common stock plus an estimated control premium, was less than the book value of its net assets. Therefore, the required next analysis of the assessment was performed (step 2), in which the implied fair value of the Company's goodwill was compared to the book value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination, that is, the estimated fair value of the Company is allocated to all of those assets and liabilities (including both recognized and unrecognized intangible assets) as if the Company had been acquired in a business combination and the estimated fair value was the purchase price paid. If the carrying amount of goodwill is greater than the implied fair value of goodwill, an impairment loss is recognized in the amount of the excess and is charged to operations.

As a result of our preliminary interim impairment assessment, the Company recognized a non-cash goodwill impairment charge of $4.4 million as of September 30, 2011, representing the entire balance of goodwill. The Company subsequently finalized its analysis with no change to the preliminary results. In addition, the Company also reviewed the carrying value of intangible assets, which is limited to our ancillary provider network and property and equipment, to determine if impairment exists. Based on this analysis, the Company concluded that no impairment of the ancillary provider network or property and equipment existed as of September 30, 2011. A deferred tax benefit of $1.5 million was recognized as of September 30, 2011 as a result of the total amount of estimated impairment charges, but a valuation allowance was immediately provided.

The impairment was indicated as a result of the decline in the Company's stock price which the Company believes was caused by the continued declines in revenue and claims volume from the Company's two most significant clients and the expectation of significantly diminishing revenue from at least one of these clients. The impairment did not impact cash flows.

Intangibles

The ancillary provider network is being amortized using the straight-line method over their expected useful lives of 15 years.  Experience to date is that approximately 2-5% annual turnover or attrition of provider contracts occurs each year.  The ancillary provider network is being accounted for on a pooled basis and the actual cancellation rates of provider contracts that were acquired are monitored for potential impairment or amortization adjustment, if warranted.  As of December 31, 2011 and 2010, there were no indicators of impairment of the intangible assets.  The cost of adding additional providers is considered an ongoing operating expense.    

The following is a summary of our intangible assets as of December 31 for the years presented: 

	2011			2010
Ancillary provider network	$	1,921		$	1,921
Software	428			428
	2,349			2,349
Accumulated amortization	(1,453		)	(1,324		)
Intangibles, net	$	896		$	1,025

The capitalized value of the ancillary provider network that was acquired in the 2003 acquisition of the assets of our predecessor, American CareSource Corporation by Patient Infosystems (now CareGuide, Inc.), our former parent corporation. Amortization expense was approximately $128,000 for each of the years ended December 31, 2011 and 2010.  Amortization expense is estimated at $128,000 per year through 2018.

F-9

7. Commitments and Contingencies

The Company leases office space under a non-cancelable lease agreement, which expires in March 2013. In late 2011, the Company amended this agreement thereby partially terminating vacant space and reducing rent expense. Additionally the Company leases certain equipment under non-cancelable lease agreements, which expire at various dates through October 2014.

At December 31, 2011 minimum annual lease payments for operating leases are approximately as follows:

	Operating Leases
2012	$	380
2013	108
2014	14
Total minimum lease payments	$	502

Expense related to operating leases was approximately $347,000 and $363,000 for the years ended December 31, 2011 and 2010, respectively.

8. Stock-Based Compensation

Stock Options

American CareSource Holdings, Inc. has an Employee Stock Option Plan (the “Stock Option Plan”) for the benefit of certain employees, non-employee directors, and key advisors.  On May 16, 2005, the stockholders approved the 2005 Stock Option Plan which (i) authorized options to purchase 2,249,329 shares and (ii) established the class of eligible participants to include employees, nominees to the Board of Directors of American CareSource Holdings and consultants engaged by American CareSource Holdings, limited to 50,000 shares of Common Stock underlying the one-time grant of a Non-Qualified Option to which non-employee directors or non-employee nominees of the Board of Directors may be entitled.  Stock options granted under the Stock Option Plan may be of two types:  (1) incentive stock options and (2) nonqualified stock options.  The option price of such grants shall be determined by a Committee of the Board of Directors (the “Committee”), but shall not be less than the estimated fair value of the common stock at the date the option is granted.  The Committee shall fix the terms of the grants with no option term lasting longer than ten years.  The ability to exercise such options shall be determined by the Committee when the options are granted.

Over time this plan has been amended to increase the number of shares available to a total of 3,749,329 shares.

On May 19, 2009, the stockholders of the Company approved the 2009 Equity Incentive Plan (the “2009 Plan”).  The purpose of the 2009 Plan is (a) to allow selected employees and officers of the Company to acquire and increase equity ownership in the Company, which will strengthen their commitment to the success of the Company, and to attract new employees, officers and consultants, (b) to provide annual cash incentive compensation opportunities that are competitive with other peer corporations, (c) to optimize the profitability and growth of the Company through incentives that are consistent with the Company’s goals, (d) to provide grantees an incentive for individual excellence, (e) to promote teamwork and (f) to attract and retain highly-qualified persons to serve as non-employee directors.  The 2009 Plan allows for awards of non-qualified options, stock appreciation rights, restricted shares, performance units/shares, deferred stock, dividend equivalents and other stock-based awards up to 1,500,000 shares.  The term of the 2009 Plan is ten years and all non-qualified options will be valued at not less than 100% of the market value of the Company’s stock on the date of grant.

Shares of common stock reserved for future grants under the Stock Option Plan and the 2009 Plan (the “Plans”) were 1,640,869 and 1,502,813 at December 31, 2011 and 2010, respectively.

Compensation expense related to all equity awards, including non-qualified stock options and restricted stock units, that has been charged against income for the years ended December 31, 2011 and 2010 was approximately $738,000 and $871,000, respectively.

F-10

The awards granted to employees and non-employee directors become exercisable over periods of up to five years.  The fair value of each option award granted is estimated on the date of grant using the Black-Scholes-Merton valuation model that uses the assumptions noted in the following table.  Volatility is calculated using an analysis of historical volatility.  The Company believes that the historical volatility of the Company’s stock is the best method for estimating future volatility.  The expected lives of options are determined based on the Company’s historical share option exercise experience.  The Company believes the historical experience method is the best estimate of future exercise patterns currently available.  The risk-free interest rates are determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the options.  The expected dividend yields are based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant. 

	2011			2010
Weighted average grant date fair value	$	0.63		$	1.04
Weighted average assumptions used
Expected volatility	66.9		%	69.3		%
Expected lives (years)	6.1			6.3
Risk free interest rate	1.6		%	2.6		%
Forfeiture rate	20.5		%	20.5		%
Dividend rate	—			—

A summary of stock option activity is as follows:

	Options (thousands)		Weighted-Average Exercise Price
Outstanding at December 31, 2009	2,488		$	3.52
Granted	964		$	1.70
Forfeited	(479	)	$	5.25
Cancelled	(374	)	$	5.47
Outstanding at December 31, 2010	2,599		$	2.24
Granted	280		$	1.03
Forfeited	(165	)	$	2.11
Cancelled	(235	)	$	2.94
Exercised	(261	)	$	0.37
Outstanding at December 31, 2011	2,218		$	2.24
Exercisable at December 31, 2011	1,318		$	2.45

As of December 31, 2011, the weighted average remaining contractual life of the options outstanding was 7.1 years and the weighted average remaining contractual life of the outstanding exercisable options was 6.1 years.

The following table summarizes information concerning outstanding and exercisable options at December 31, 2011:

(in thousands)	Options Outstanding				Options Exercisable
Range of Exercise Price	Number Outstanding	Weighted Average Outstanding Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
Under $1.00	349	6.4	$	0.50	229	$	0.41
$1.00 - $2.00	939	7.4	$	1.65	536	$	1.77
$2.01 - $3.00	519	7.6	$	2.23	224	$	2.45
$3.01 - $4.00	45	6.2	$	3.29	42	$	3.29
$4.01 - $5.00	208	6.4	$	4.17	169	$	4.18
$5.01 - $6.00	50	4.1	$	5.60	50	$	5.60
$6.01 - $7.00	7	6.9	$	7.00	5	$	7.00
Greater than $7.01	101	7.0	$	7.35	63	$	7.49

F-11

The total intrinsic value of options outstanding at December 31, 2011 and 2010 was approximately $21,000 and $465,000, respectively.  The total intrinsic value of the options that are exercisable at December 31, 2011 and 2010 was approximately $21,000 and $462,000, respectively. The total intrinsic value of options exercised during the year ended December 31, 2011 was approximately $127,000. No options were exercised during the year ended December 31, 2010.

Compensation expense related to non-qualified stock options charged to operations during 2011 was approximately $630,000. As of December 31, 2011, there was approximately $778,000 of total unrecognized compensation cost related to non-vested non-qualified stock options granted under the plan.  The cost is expected to be recognized over a weighted average period of 3.1 years.

Restricted Stock Units

Under the 2009 Plan, the Company issued restricted stock units (“RSUs”) to certain employees and the Board of Directors during the twelve months ended December 31, 2009.  As RSUs vest, they are convertible into shares of the Company’s common stock.  The RSUs are valued at the market price of the Company’s stock on the measurement date, which is the date of grant. Compensation expense is recognized ratably over the vesting period.  Our future estimated forfeiture rate on RSUs is 0% as the RSUs have been awarded primarily to members of our Board of Directors and members of senior management of the Company. No RSUs were issued during the twelve months ended December 31, 2011 and 2010.

A summary of RSU activity is as follows:

	RSUs		Weighted-Average Grant Date Fair Value
Outstanding at December 31, 2009	140		$	6.99
Forfeited	(23	)	$	6.68
Converted to common stock	(31	)	$	7.02
Outstanding at December 31, 2010	86		$	7.07
Forfeited	(18	)	$	1.86
Converted to common stock	(50	)	$	3.87
Outstanding at December 31, 2011	18		$	7.15
Vested and convertible to common stock at December 31, 2011	3		$	7.02

Compensation expense related to RSUs charged to operations during 2011 and 2010 was approximately $108,000 and $272,000, respectively. As of December 31, 2011, there was approximately $86,000 of total unrecognized compensation cost related to non-vested RSUs granted under the plan. The cost is expected to be recognized over a weighted average period of 2.3 years.

9. Stock Warrants

On July 2, 2007, the Company announced that it had signed an Ancillary Care Services Network Access Agreement (the “Ancillary Care Services Agreement”) effective as of May 21, 2007 (the “Effective Date”) with a new client, Texas True Choice, Inc. (“Texas True Choice”), a Texas-based preferred provider organization network, and certain subsidiaries of Texas True Choice. As partial compensation to Texas True Choice under the Ancillary Care Services Agreement, the Company issued to Corporate Health Plans of America, Inc., an affiliate of Texas True Choice, warrants to purchase a total of 225,000 shares of the Company’s common stock at an exercise price of $1.84, the closing price of the common stock of the Company as reported on the American Stock Exchange on the Effective Date. The Company valued the warrants when various measurement dates had been reached under the agreement.  Utilizing the Black-Scholes Merton valuation method, 112,500 warrants were valued at $0.94 in 2007, 56,250 warrants were valued at $2.87 at June 2008 and the remaining 56,250 were valued at $5.53 in June 2009.

These warrants vested 25% on the Effective Date, an additional 25% on each anniversary date of the Effective Date, and have an expiration date of May 20, 2012. As of December 31, 2010, all warrants to purchase shares of the Company's common stock were fully vested. The Company recorded the value of warrants as deferred costs upon vesting and amortized the deferred costs as administrative fees over the related contract term. As of December 31, 2010, the total unrecognized cost related to the warrants of approximately $67,000 was included as Prepaid and Other Current Assets and recognized as an expense through the term of the contract which expired in June 2011.  The weighted average remaining contractual life of the warrants is 0.8 years.

F-12

The Company entered into an agreement as of February 25, 2011 with an employee, whereby the Company agreed to issue warrants to purchase 250,000 shares of common stock with an exercise price of $1.67. The warrants vest in increments pursuant to the achievement of defined, agreed upon revenue targets generated by new clients within a five year term. The agreement also obligates the Company to issue warrants to purchase up to an additional 500,000 shares of common stock (issued in 250,000 increments) pursuant to the achievement of additional defined agreed upon revenue targets. During the twelve months ended December 31, 2011, we did not recognize compensation costs associated with these warrants due to the probability of vesting. That probability will be re-evaluated and updated based on current market conditions, on a quarterly basis, and compensation costs will be adjusted accordingly.

On February 1, 2012, certain terms of the agreement were modified, including the revenue targets and the total number of shares under the initial and future warrants. The warrant issuance now allows for 133,334 shares to be purchased at an exercise price of $0.50, 66,667 of which are vested, and the remaining 66,667 shares vesting upon the achievement of certain revenue targets. The number of shares under the future warrant issuances was also reduced to 266,666 (issued in 133,333 increments) shares based upon the achievement of additional defined agreed upon revenue targets.

A summary of stock warrant activity is as follows:

	Outstanding Warrants (thousands)		Weighted-Average Exercise Price
Outstanding at December 31, 2009	1,827		$	0.89
Exercised	(1,502	)	$	0.44
Outstanding at December 31, 2010	325		$	2.96
Granted	250		$	1.67
Cancelled	(100	)	$	5.51
Outstanding at December 31, 2011	475		$	1.75
Vested at December 31, 2011	225		$	1.84

10. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (or loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings (loss) per share reflects the potential dilution that could occur if options, warrants and restricted stock units to purchase common stock were exercised or converted. For purposes of this calculation, outstanding stock options, stock warrants and restricted stock units are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding.  

For the year ended December 31, 2011, options to purchase approximately 2.0 million shares of commons stock, warrants to purchase approximately 475,000 shares of common stock, and approximately 15,000 unvested restricted stock units were excluded from the calculation as their impact would be anti-dilutive.

F-13

The following table details the reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share (amounts in thousands except per share amounts):

	2011			2010
Numerator:
Net income (loss) for basic earnings per share	$	(7,237	)	$	486
Less:
Change in fair value of warrant derivative liability	—			18
Net income for diluted earnings (loss) per share	$	(7,237	)	$	468
Denominator:
Weighted-average basic common shares outstanding	17,005			16,550
Assumed conversion of dilutive securities:
Stock options	—			271
Warrants	—			355
Restricted stock units	—			—
Potentially dilutive common shares	—			626
Denominator for diluted earnings (loss) per share – Adjusted weighted-average shares	17,005			17,176
Earnings (loss) per common share:
Basic	$	(0.43	)	$	0.03
Diluted	$	(0.43	)	$	0.03

11. Significant Agreements

During the year ended December 31, 2010, an ancillary service provider terminated its agreement with the Company to provide laboratory services in Texas to clients of the Company on an “as needed” basis.  Services provided by the provider accounted for approximately 3% of the Company’s net revenues in 2010.

The Company's second largest client continues to transition its payors and employer groups to alternative network options as a result of a business combination. While the Company has an enforceable contract in effect through May 2012, the client continues its transition, negatively impacting the claims volume and revenue generated from the account. The Company anticipates the transition will continue throughout 2012 and will be complete by December 31, 2012.

12. Employee Benefit Plans

The Company provides a defined contribution plan for employees meeting minimum service requirements.  Employees can contribute up to 100% of their current compensation to the plan subject to certain statutory limitations.  The Company contributes up to a maximum of 3.5% of an employee’s compensation and plan participants are fully-vested in the Company’s contributions immediately.  The Company made contributions to the plan and charged operations approximately $120,000 and $123,000 during the years ended December 31, 2011 and 2010, respectively.

13. Quarterly Financial Information (unaudited)

The following table contains selected financial information from unaudited statements of operations for each quarter of 2011 and 2010.

	Quarters Ended
	2011											2010
	Dec. 31		Sept. 30			June 30			Mar. 31			Dec. 31		Sept. 30		June 30		Mar. 31
Net revenues	$	13,025	$	11,496		$	11,308		$	13,077		$	16,109	$	14,763	$	15,958	$	14,371
Contribution margin	1,647		781			844			1,489			1,678		1,706		2,098		1,968
Contribution margin %	12.6		6.8			7.5			11.4			10.4		11.6		13.1		13.7
Income (loss) before income taxes	150		(5,554		)	(965		)	(224		)	33		87		450		27
Net income (loss)	153		(6,523		)	(645		)	(222		)	142		44		299		1
Earnings (loss) per diluted share	0.01		(0.38		)	(0.04		)	(0.01		)	0.01		0.00		0.02		0.00
Shares used in computing diluted earnings (loss) per share	17,149		17,011			16,962			16,962			17,193		17,124		17,120		16,203

F-14

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICAN CARESOURCE HOLDINGS, INC.

By: /s/ Kenneth S. George	March 9, 2012
Kenneth S. George Chief Executive Officer	Date

Pursuant to the requirements the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

By: /s/ Kenneth S. George	March 9, 2012
Kenneth S. George Chief Executive Officer (Principal Executive Officer) Chairman of the Board of Directors	Date

By: /s/ Matthew D. Thompson	March 9, 2012
Matthew D. Thompson Chief Financial Officer   (Principal Financial Officer and Principal Accounting Officer)	Date

By: /s/ William J. Simpson, Jr.	March 9, 2012
William J. Simpson, Jr. President and Chief Operating Officer   Director	Date

By: /s/ Sami S. Abbasi	March 9, 2012
Sami S. Abbasi Director	Date

By: /s/ Edward B. Berger	March 9, 2012
Edward B. Berger Director	Date

By: /s/ John N. Hatsopoulos	March 9, 2012
John N. Hatsopoulos Director	Date

By: /s/ Matthew P. Kinley	March 9, 2012
Matthew P. Kinley Director	Date

By: /s/ John Pappajohn	March 9, 2012
John Pappajohn Director	Date

By: /s/ Derace L. Schaffer	March 9, 2012
Derace L. Schaffer Director	Date

By: /s/ Richard W. Turner	March 9, 2012
Richard W. Turner, Ph.D. Director	Date

EXHIBIT INDEX

Exhibit #	Description of Exhibits
3.1(12)	Certificate of Incorporation of American CareSource Holdings, Inc., as amended
3.2(1)	By-Laws
4.1(2)	Specimen Stock Certificate
4.2(3)	Amended and Restated 2005 Stock Option Plan
4.3 (4)	2009 Equity Incentive Plan
10.02(2), *	Employment Agreement dated May 1, 2005 between American CareSource Holdings, Inc. and David Boone
10.08(6), *	Employment Letter dated January 29, 2008 between American CareSource Holdings, Inc. and Cornelia Outten
10.09(6), *	Employment Letter dated March 6, 2008 between American CareSource Holdings, Inc. and Rost Ginevich
10.10(7)	Form of Registration Rights Agreement used in March 2006 private placement
10.11(7)	Form of Subscription Agreement used in March 2006 private placement
10.17(8)	Lease dated June 14, 2006, between American CareSource Holdings, Inc. and TR LBJ Campus Partners, L.P.
10.18(9)	First Amendment to Office Lease, dated December 1, 2008, between American CareSource Holdings, Inc. and TR LBJ Campus Partners, L.P.
10.19(10), ***	Provider Services Agreement, dated as of August 1, 2002, by and among the Company, HealthSmart Holdings, Inc. and HealthSmart Preferred Care II, L.P, and Amendment No. 1, 2, 3 and 4 thereto, dated September 1, 2005, January 1, 2007, July 31, 2007 and December 20, 2008, respectively.
10.20(9), *	Employment Letter dated November 10, 2008 between American CareSource Holdings, Inc. and James T. Robinson
10.21(10), ***	Ancillary Care Services Network Access Agreement, dated as of July 2, 2007, by and between the Company and Texas True Choice, Inc. and its subsidiaries and Amendment dated December 31, 2009.
10.22(11), *	Letter Agreement dated December 24, 2009 by and between American CareSource Holdings, Inc. and James T. Robinson
10.24 *, **	Employment Agreement dated April 29, 2011 between American CareSource Holdings, Inc. and William J. Simpson, Jr.
10.25 *, **	Employment Agreement dated April 29, 2011 between American CareSource Holdings, Inc. and Matthew D. Thompson
14.1(7)	Code of Ethics
21.1(12)	Subsidiaries

23.1**	Consent of McGladrey & Pullen LLP
31.1**	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2**	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* Designates a management contract or compensatory plan or arrangement required to be filed as an exhibit to this report pursuant to Item 15(a)(3) of this report.

** Filed herewith

*** Certain confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

(1) Previously filed with the Securities and Exchange Commission as an exhibit to Amendment No. 1 to the Form SB-2 filed May 13, 2005 and incorporated herein by reference.

(2) Previously filed with the Securities and Exchange Commission as an exhibit to Amendment No. 5 to the Form SB-2 filed August 12, 2005 and incorporated herein by reference.

(3) Previously filed with the Securities and Exchange Commission as Exhibit B to the Proxy Statement for the 2009 Annual Meeting of Stockholders filed on April 20, 2009 and incorporated herein by reference.

(4) Previously filed with the Securities and Exchange Commission as Exhibit A to the Proxy Statement for the 2009 Annual Meeting of Stockholders filed on April 20, 2009 and incorporated herein by reference.

(5) Intentionally omitted.

(6) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-K filed March 31, 2008 and incorporated herein by reference.

(7) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-KSB filed March 31, 2006 and incorporated herein by reference.

(8) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-QSB filed August 11, 2006 and incorporated herein by reference.

(9) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-K filed March 31, 2009 and incorporated herein by reference.

(10) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-Q/A filed July 8, 2011 and incorporated herein by reference.

(11) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-K filed March, 26, 2010 and incorporated herein by reference.

(12) Previously filed with the Securities and Exchange Commission as an exhibit to the Form 10-K filed March, 18, 2011 and incorporated herein by reference.

EX-10.24

Exhibit 10.24

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is entered into as of April 29, 2011, by and between American CareSource Holdings, Inc., a Delaware corporation (the “Company”), and William J. Simpson, Jr. (“Employee”).

In consideration of the mutual covenants and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1.Employment. The Company hereby employs Employee in the capacity of Chief Operating Officer. Employee accepts such employment and agrees to perform such services as are customary to such office and as shall from time to time be assigned to him by the Board of Directors of the Company.

2.Term. The employment hereunder shall be for a period commencing on January 1, 2011, (the “Commencement Date”) and ending on December 31, 2011 (the “Initial Term”), unless earlier terminated as provided in Section 5. This Agreement shall be automatically renewed for successive one-year periods upon the expiration of the Initial Term unless earlier terminated as provided in Section 5. Employee's employment will be on a full-time business basis requiring the devotion of substantially all of his productive business time for the efficient and successful operation of the business of the Company with the exception of pre-approved positions such as outside board membership etc.

3.Compensation and Benefits

3.1Salary. For the performance of Employee's duties hereunder, the Company shall pay Employee an annual salary in the amount of $225,000 (the “Base Compensation”). The Employee's salary will be reviewed annually with each anniversary date of the Commencement Date over the term of this employment contract.

3.2Bonus Plan. Employee shall be entitled to a bonus determined at the sole discretion of the Board of Directors of the Company or the Compensation Committee thereof pursuant to a bonus compensation plan provided in written detail to Employee within a reasonable time prior to the beginning of the period of time from which the performance of the Employee would be evaluated and measured for such bonus. .

3.3    Stock Options. From time to time the Company may grant to Employee options under the Company's Stock Option Plan to purchase shares of the Company's common stock at a stated exercise price per share. Any options granted will vest and be exercisable in accordance with a Stock Option Agreement to be executed pursuant to the Company's Stock Option Plan.

3.4    Benefits. Employee shall be entitled to such medical, disability and life insurance coverage and such vacation, sick leave and holiday benefits, if any, and any other benefits as are made available to the Company's personnel, all in accordance with the Company's benefits program in effect from time to time and employee shall accrue four weeks vacation over 12 months from date hereof. The Employee is responsible for paying the employee's portion of the benefit costs. The benefits provided to Employee under this Section 3.4 shall terminate immediately upon a Termination Event pursuant to Section 5 hereof unless otherwise provided for in such Section 5.

3.5Reimbursement of Expenses. Employee shall be entitled to be reimbursed for all reasonable expenses, including but not limited to expenses for travel, meals and entertainment, incurred by Employee in connection with and reasonably related to the furtherance of the Company's business. Employee shall submit expense reports and receipts documenting the expenses incurred in accordance with Company policy.

4.Change of Control. In the event of a Change of Control of the Company (as defined below), all options and other equity incentives then granted to Employee, if any, which are unvested at the date of the Change of Control shall immediately vest and be exercisable.

In addition, in lieu of the provisions of Section 5.2(b), in the event of a termination of Employee's employment hereunder by the Company with or without Cause, or by Employee with or without Good Reason (as defined below), within 12 months following a Change of Control, the Company will promptly pay Employee, in lieu of the amounts required under Section 5.2(b) and in addition to the amounts required under Section 5.2(a), a severance amount, payable in a lump sum immediately upon such termination of employment, equal to six (6) months base compensation.

As used herein, a “Change of Control” of the Company shall mean any of the following: (i) the acquisition by any person (individual, entity or group) of direct or beneficial ownership of more than 50% of the then outstanding shares of the Company and, for this purpose, the terms “person” and “beneficial ownership” shall have the meanings provided in Section 13(d) or 14(d) of the Securities Exchange Act of 1934 or related rules promulgated by the Securities and Exchange Commission; (ii) a sale of all or substantially all of the assets of the Company; or (iii) the Board of Directors of the Company, in its sole and absolute discretion, determines that there has been a sufficient change in the stock ownership of the Company to constitute a change in control of the Company. Notwithstanding the foregoing, the following acquisitions shall not constitute a “Change of Control”: (1) any acquisition by the Company; or (2) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company.

5.Termination

5.1Termination Events. The employment hereunder will terminate upon the occurrence of any of the following events (“the Termination Event”):

(a)Employee dies, in which case the Company shall continue to pay the Base Compensation to the estate of the Employee for a period of ninety (90) days after such death;

(b)The Company, by written notice to Employee or his personal representative, discharges Employee due to the inability to continue to perform the duties previously assigned to him prior to such injury or disability hereunder for a continuous period exceeding 180 days by reason of injury, physical or mental illness or other disability, which condition has been certified by a physician acceptable to the Company; provided, however, that prior to discharging Employee due to such disability, the Company shall give a written statement of findings to Employee or his personal representative setting forth specifically the nature of the disability and the resulting performance failures, and Employee shall have a period of thirty (30) days thereafter to respond in writing to the Company's findings, whereupon the Company shall conduct a reasonable and fair hearing with the Employee and any supporting witnesses and evidence for the Employee to reach a final determination;

(c)Employee is discharged by the Company for “Cause”. As used in this Agreement, the term “Cause” shall mean:

(i)Material breach by the Employee of any provision of this Agreement, which breach, if susceptible to cure, shall not have been cured by the Employee within ten (10) days of receipt of written notice of said breach;

(ii)Misconduct as an employee of the Company, including but not limited to: misappropriating any funds or property of the Company; attempting to willfully obtain any personal profit from any transaction in which the Employee has an interest which is adverse to the interests of the Company; or any other act or omission which substantially impairs the Company's ability to conduct its ordinary business in its usual manner;

(iii)Unreasonable neglect or refusal to perform the duties assigned to the Employee under or pursuant to this Agreement;

(iv)Conviction of or plea of nolo contendere to a felony;

(v)The possession or use by the Employee of illegal drugs or prohibited substances, the excessive drinking of alcoholic beverages on a recurring basis which impairs the Employee's ability to perform his duties under this Agreement, or the appearance during hours of employment on a recurring basis of being under the influence of such drugs, substances or alcohol; or

(vi)Any other act or omission which subjects the Company or any of its subsidiaries to substantial public disrespect, scandal or ridicule.

(d)Employee is discharged by Company “without Cause”, which the Company may do at any time, with at least thirty (30) days advance written notice, subject to the full performance of the obligations of the Company to the Employee for Base Compensation and bonus payments pursuant to Section 5.2; or

(e)Employee voluntarily terminates his employment due to “Good Reason”, which shall mean a material default by the Company in the performance of any of its obligations hereunder, which default remains uncured by the Company for a period of thirty (30) days following receipt of written notice thereof to the Company from Employee or

(f)Employee voluntarily terminates his employment without Good Reason, which Employee may do at any time with at least 30 days advance notice.

5.2Effects of Termination

(a)Upon termination of Employee's employment hereunder for any reason, the Company will promptly pay Employee all Base Compensation owed to Employee (including, without limitation, salary and employee expenses reimbursements). Employee shall be paid for any performance bonus plan as provided for in Section 3.2 then in effect on a pro rata basis for that period of time during the fiscal year in which termination occurs, but such amount, if any shall only be paid at a commensurate time as other employees are paid their bonus amounts and in accordance with the terms of such plan (including any provisions thereof that provide for the exercise of discretion by the Board or the Compensation Committee of the Board of Directors). To the extent required by law, the Company shall pay or otherwise provide for any benefits, payments or continuation or conversion rights in accordance with the provision of any benefit plan of which the Employee or any of his dependents is or was a participant.

(b)Upon termination of Employee's employment under Sections 5.1(b), (d) or (e), the Company shall pay Employee, commencing immediately upon such termination of employment, monthly (or biweekly at the Company's discretion) amounts equal to the then applicable Base Compensation, excluding bonus, for a period of six (6) months after termination. Benefits will also continue for a period of six (6) months at the same cost to the Employee.

(c)Upon termination of Employee's employment hereunder; Employee agrees that (A) for the twelve (12) month period following the Termination Event, if Employee's employment is terminated pursuant to Sections 5.1(b), (c) or (f) or (B) for the six (6) month period following the Termination Event, if Employee's employment is terminated pursuant to Section 5.1(d) or (e):

(i)Employee will not directly or indirectly, whether as an individual, employee, director, consultant or advisor, or in any other capacity whatsoever, provide services to any person, firm, corporation or other business enterprise which is involved in the business of disease management, ancillary claims management, or ancillary benefits management in competition with the Company, unless he obtains the Company's prior written consent.

(ii)Employee will not directly or indirectly encourage or solicit, or attempt to encourage or solicit, any individual to leave the Company's employ for any reason or interfere in any other manner with the employment relationships at the time existing between the Company and its current employees.

(iii)Employee will not induce or attempt to induce any provider, agent, customer, supplier, distributor, licensee or other business relation of the Company to cease doing business with the Company or in any way interfere with the existing business relationship between any such providers, agent, customer, supplier, distributor, licensee or other business relation and the Company.

Employee acknowledges that monetary damages may not be sufficient to compensate the Company for any economic loss, which may be incurred by reason of breach of the foregoing restrictive covenants. Accordingly, in the event of any such breach, the Company shall, in addition to any remedies available to the Company at law, be entitled to obtain equitable relief in the form of an injunction, precluding Employee from continuing to engage in such breach.

If any restriction set forth in this paragraph is held to be unreasonable, then Employee and the Company agree, and hereby submit, to the reduction and limitation of such prohibition to such area or period as shall be deemed reasonable

(d)Following a Termination Event, Employee agrees not to make to any person, including but not limited to customers of the Company, any statement that disparages the Company or which reflects negatively upon the Company, including but not limited to statements regarding the Company's financial condition, its officers, directors, shareholders, employees and affiliates. The Company agrees not to make to any person, including but not limited to customers of the Company, any statement that disparages Employee or which reflects negatively upon Employee, including but not limited to statements regarding his financial condition.

(e)The Employee agrees that the payments and/or benefits described in this Agreement shall be his sole and exclusive remedy in the event that the Company terminates his employment, and he shall be entitled to no further compensation for any damage or injury arising out of the termination of his employment by the Company, including payments or benefits set forth in any severance pay policy maintained by the Company, the payments and/or benefits so described being in full and complete satisfaction of any and all obligations owing to the Employee pursuant to this Agreement or otherwise in connection with the Employee's employment, and the Executive shall provide an unconditional release of the Company and its subsidiaries and affiliates, and their respective directors, officers, employees and stockholders, or any of them, from any and all claims, liabilities or obligations under any severance or termination arrangements of the Company or any of its subsidiaries or affiliates, or otherwise related to the Employee's employment with the Company in exchange for (and as a condition to receipt of) such payments.

6.General Provisions

6.1Assignment. Neither party may assign or delegate any of his or its rights or obligations under this Agreement without the prior written consent of the other party.

6.2Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all prior agreements between the parties.

6.3    Modifications. This Agreement may be changed or modified only by an agreement in writing signed by both parties hereto.

6.4    Prior Agreements. This Agreement supersedes all prior written and verbal agreements with the Company and/or its Board of Directors and shall govern all future employment obligations.

6.5    Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and permitted assigns and Employee and Employee's legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join and be bound by the terms and conditions hereof.

6.6Governing Law. This Agreement shall be governed by, construed and enforced in accordance with, the laws of the State of Texas, and venue and jurisdiction for any disputes hereunder shall be heard in any court of competent jurisdiction in Dallas, Texas for all purposes.

6.7Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nevertheless continue in full force and effect.

6.8Further Assurances. The parties will execute such further instruments and take such further actions as may be reasonably necessary to carry out the intent of this Agreement.

6.9Notices. Any notices or other communications required or permitted hereunder shall be in writing and shall be deemed received by the recipient when delivered personally or, if mailed, five (5) days after the date of deposit in the United States mail, certified or registered, postage prepaid and addressed, in the case of the Company, to:

Chief Financial Officer

American CareSource Holdings, Inc.

5429 Lyndon B. Johnson Freeway

Suite 700

Dallas, TX 75240

and in the case of Employee, to the address shown for Employee on the signature page hereof, or to such other address as either party may later specify by at least ten (10) days advance written notice delivered to the other party in accordance herewith.

6.10No Waiver. The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver of that provision, nor prevent that party thereafter from enforcing that provision of any other provision of this Agreement.

6.11Legal Fees and Expenses. In the event of any disputes under this Agreement, each party shall be responsible for their own legal fees and expenses which it may incur in resolving such dispute, unless otherwise prohibited by applicable law or a court of competent jurisdiction.

6.12Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Company and Employee have executed this Agreement, effective as of the day and year first above written.

American CareSource Holdings, Inc.

By: /s/ Kenneth S. George

Kenneth S. George, Chairman of the Board

EMPLOYEE:

By: /s/ William J. Simpson, Jr.

William J. Simpson, Jr.

EX-10.25

Exhibit 10.25

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is entered into as of April 29, 2011, by and between American CareSource Holdings, Inc., a Delaware corporation (the “Company”), and Matthew D. Thompson (“Employee”).

In consideration of the mutual covenants and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1.    Employment. The Company hereby employs Employee in the capacity of Chief Financial Officer. Employee accepts such employment and agrees to perform such services as are customary to such office and as shall from time to time be assigned to him by the Chief Operating Officer or the Board of Directors of the Company.

2.    Term. The employment hereunder shall be for a period commencing on July 20, 2010 (the “Commencement Date”) and ending on July 19, 2011 (the “Initial Term”), unless earlier terminated as provided in Section 5. This Agreement shall be automatically renewed for successive one-year periods upon the expiration of the Initial Term unless earlier terminated as provided in Section 5. Employee’s employment will be on a full-time business basis requiring the devotion of substantially all of his productive business time for the efficient and successful operation of the business of the Company with the exception of pre approved positions such as outside board membership etc.

3.    Compensation and Benefits

3.1    Salary. For the performance of Employee’s duties hereunder, the Company shall pay Employee an annual salary in the amount of $185,000 (the “Base Compensation”). The Employee’s salary will be reviewed annually with each anniversary date of the Commencement Date over the term of this employment contract.

3.2    Bonus Plan. Employee shall be entitled to a bonus determined at the sole discretion of the Board of Directors of the Company or the Compensation Committee thereof pursuant to a bonus compensation plan provided in written detail to Employee within a reasonable time prior to the beginning of the period of time from which the performance of the Employee would be evaluated and measured for such bonus. .

3.3Stock Options.

(a)From time to time the Company may grant to Employee options under the Company’s Stock Option Plan to purchase shares of the Company’s common stock at a stated exercise price per share. Any options granted will vest and be exercisable in accordance with a Stock Option Agreement to be executed pursuant to the Company’s Stock Option Plan.

(b)Benefits. Employee shall be entitled to such medical, disability and life insurance coverage and such vacation, sick leave and holiday benefits, if any, and any other benefits as are made available to the Company’s personnel, all in accordance with the Company’s benefits program in effect from time to time and employee shall accrue four weeks vacation over 12 months from date hereof. The Employee is responsible for paying the employee’s portion of the benefit costs. The benefits provided to Employee under this Section 3.4 shall terminate immediately upon a Termination Event pursuant to Section 5 hereof unless otherwise provided for in such Section 5.

3.5    Reimbursement of Expenses. Employee shall be entitled to be reimbursed for all reasonable expenses, including but not limited to expenses for travel, meals and entertainment, incurred by Employee in connection with and reasonably related to the furtherance of the Company’s business. Employee shall submit expense reports and receipts documenting the expenses incurred in accordance with Company policy.

4.    Change of Control. In the event of a Change of Control of the Company (as defined below), all options and other equity incentives then granted to Employee, if any, which are unvested at the date of the Change of Control shall immediately vest and be exercisable.

In addition, in lieu of the provisions of Section 5.2(b), in the event of a termination of Employee’s employment hereunder by the Company with or without Cause, or by Employee with or without Good Reason (as defined below), within 12 months following a Change of Control, the Company will promptly pay Employee, in lieu of the amounts required under Section 5.2(b) and in addition to the amounts required under Section 5.2(a), a severance amount, payable in a lump sum immediately upon such termination of employment, equal to six (6) months base compensation.

As used herein, a “Change of Control” of the Company shall mean any of the following: (i) the acquisition by any person (individual, entity or group) of direct or beneficial ownership of more than 50% of the then outstanding shares of the Company and, for this purpose, the terms “person” and “beneficial ownership” shall have the meanings provided in Section 13(d) or 14(d) of the Securities Exchange Act of 1934 or related rules promulgated by the Securities and Exchange Commission; (ii) a sale of all or substantially all of the assets of the Company; or (iii) the Board of Directors of the Company, in its sole and absolute discretion, determines that there has been a sufficient change in the stock ownership of the Company to constitute a change in control of the Company. Notwithstanding the foregoing, the following acquisitions shall not constitute a “Change of Control”: (1) any acquisition by the Company; or (2) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company.

5.    Termination

5.1    Termination Events. The employment hereunder will terminate upon the occurrence of any of the following events (“the Termination Event”):

(a)    Employee dies, in which case the Company shall continue to pay the Base Compensation to the estate of the Employee for a period of ninety (90) days after such death;

(b)    The Company, by written notice to Employee or his personal representative, discharges Employee due to the inability to continue to perform the duties previously assigned to him prior to such injury or disability hereunder for a continuous period exceeding 180 days by reason of injury, physical or mental illness or other disability, which condition has been certified by a physician acceptable to the Company; provided, however, that prior to discharging Employee due to such disability, the Company shall give a written statement of findings to Employee or his personal representative setting forth specifically the nature of the disability and the resulting performance failures, and Employee shall have a period of thirty (30) days thereafter to respond in writing to the Company’s findings, whereupon the Company shall conduct a reasonable and fair hearing with the Employee and any supporting witnesses and evidence for the Employee to reach a final determination;

(c)    Employee is discharged by the Company for “Cause”. As used in this Agreement, the term “Cause” shall mean:

(i)    Material breach by the Employee of any provision of this Agreement, which breach, if susceptible to cure, shall not have been cured by the Employee within ten (10) days of receipt of written notice of said breach;

(ii)    Misconduct as an employee of the Company, including but not limited to: misappropriating any funds or property of the Company; attempting to willfully obtain any personal profit from any transaction in which the Employee has an interest which is adverse to the interests of the Company; or any other act or omission which substantially impairs the Company’s ability to conduct its ordinary business in its usual manner;

(iii)    Unreasonable neglect or refusal to perform the duties assigned to the Employee under or pursuant to this Agreement;

(iv)    Conviction of or plea of nolo contendere to a felony;

(v)    The possession or use by the Employee of illegal drugs or prohibited substances, the excessive drinking of alcoholic beverages on a recurring basis which impairs the Employee’s ability to perform his duties under this Agreement, or the appearance during hours of employment on a recurring basis of being under the influence of such drugs, substances or alcohol; or

(vi)    Any other act or omission which subjects the Company or any of its subsidiaries to substantial public disrespect, scandal or ridicule.

(d)    Employee is discharged by Company “without Cause”, which the Company may do at any time, with at least thirty (30) days advance written notice, subject to the full performance of the obligations of the Company to the Employee for Base Compensation and bonus payments pursuant to Section 5.2; or

(e)    Employee voluntarily terminates his employment due to “Good Reason”, which shall mean a material default by the Company in the performance of any of its obligations hereunder, which default remains uncured by the Company for a period of thirty (30) days following receipt of written notice thereof to the Company from Employee or

(f)    Employee voluntarily terminates his employment without Good Reason, which Employee may do at any time with at least 30 days advance notice.

5.2    Effects of Termination

(a)    Upon termination of Employee’s employment hereunder for any reason, the Company will promptly pay Employee all Base Compensation owed to Employee (including, without limitation, salary and employee expenses reimbursements). Employee shall be paid for any performance bonus plan as provided for in Section 3.2 then in effect on a pro rata basis for that period of time during the fiscal year in which termination occurs, but such amount, if any shall only be paid at a commensurate time as other employees are paid their bonus amounts and in accordance with the terms of such plan (including any provisions thereof that provide for the exercise of discretion by the Board or the Compensation Committee of the Board of Directors). To the extent required by law, the Company shall pay or otherwise provide for any benefits, payments or continuation or conversion rights in accordance with the provision of any benefit plan of which the Employee or any of his dependents is or was a participant.

(b)    Upon termination of Employee’s employment under Sections 5.1(b), (d) or (e), the Company shall pay Employee, commencing immediately upon such termination of employment, monthly (or biweekly at the Company’s discretion) amounts equal to the then applicable Base Compensation, excluding bonus, for a period of six (6) months after termination. Benefits will also continue for a period of six (6) months at the same cost to the Employee.

(c)    Upon termination of Employee’s employment hereunder; Employee agrees that (A) for the twelve (12) month period following the Termination Event, if Employee’s employment is terminated pursuant to Sections 5.1(b), (c) or (f) or (y) for the six (B) month period following the Termination Event, if Employee’s employment is terminated pursuant to Section 5.1(d) or (e):

(i)    Employee will not directly or indirectly, whether as an individual, employee, director, consultant or advisor, or in any other capacity whatsoever, provide services to any person, firm, corporation or other business enterprise which is involved in the business of disease management, ancillary claims management, or ancillary benefits management in competition with the Company, unless he obtains the Company’s prior written consent.

(ii)    Employee will not directly or indirectly encourage or solicit, or attempt to encourage or solicit, any individual to leave the Company’s employ for any reason or interfere in any other manner with the employment relationships at the time existing between the Company and its current employees.

(iii)    Employee will not induce or attempt to induce any provider, agent, customer, supplier, distributor, licensee or other business relation of the Company to cease doing business with the Company or in any way interfere with the existing business relationship between any such providers, agent, customer, supplier, distributor, licensee or other business relation and the Company.

Employee acknowledges that monetary damages may not be sufficient to compensate the Company for any economic loss, which may be incurred by reason of breach of the foregoing restrictive covenants. Accordingly, in the event of any such breach, the Company shall, in addition to any remedies available to the Company at law, be entitled to obtain equitable relief in the form of an injunction, precluding Employee from continuing to engage in such breach.

If any restriction set forth in this paragraph is held to be unreasonable, then Employee and the Company agree, and hereby submit, to the reduction and limitation of such prohibition to such area or period as shall be deemed reasonable

(d)    Following a Termination Event, Employee agrees not to make to any person, including but not limited to customers of the Company, any statement that disparages the Company or which reflects negatively upon the Company, including but not limited to statements regarding the Company’s financial condition, its officers, directors, shareholders, employees and affiliates. The Company agrees not to make to any person, including but not limited to customers of the Company, any statement that disparages Employee or which reflects negatively upon Employee, including but not limited to statements regarding his financial condition.

(e)    The Employee agrees that the payments and/or benefits described in this Agreement shall be his sole and exclusive remedy in the event that the Company terminates his employment, and he shall be entitled to no further compensation for any damage or injury arising out of the termination of his employment by the Company, including payments or benefits set forth in any severance pay policy maintained by the Company, the payments and/or benefits so described being in full and complete satisfaction of any and all obligations owing to the Employee pursuant to this Agreement or otherwise in connection with the Employee’s employment, and the Executive shall provide an unconditional release of the Company and its subsidiaries and affiliates, and their respective directors, officers, employees and stockholders, or any of them, from any and all claims, liabilities or obligations under any severance or termination arrangements of the Company or any of its subsidiaries or affiliates, or otherwise related to the Employee’s employment with the Company in exchange for (and as a condition to receipt of) such payments.

6.    General Provisions

6.1    Assignment. Neither party may assign or delegate any of his or its rights or obligations under this Agreement without the prior written consent of the other party.

6.2    Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all prior agreements between the parties.

6.3Modifications. This Agreement may be changed or modified only by an agreement in writing signed by both parties hereto.

6.4Prior Agreements. This Agreement supercedes all prior written and verbal agreements with the Company and/or its Board of Directors and shall govern all future employment obligations.

6.5Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and permitted assigns and Employee and Employee’s legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join and be bound by the terms and conditions hereof.

6.6    Governing Law. This Agreement shall be governed by, construed and enforced in accordance with, the laws of the State of Texas, and venue and jurisdiction for any disputes hereunder shall be heard in any court of competent jurisdiction in Dallas, Texas for all purposes.

6.7    Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nevertheless continue in full force and effect.

6.8    Further Assurances. The parties will execute such further instruments and take such further actions as may be reasonably necessary to carry out the intent of this Agreement.

6.9    Notices. Any notices or other communications required or permitted hereunder shall be in writing and shall be deemed received by the recipient when delivered personally or, if mailed, five (5) days after the date of deposit in the United States mail, certified or registered, postage prepaid and addressed, in the case of the Company, to:

Chief Operating Officer

American CareSource Holdings, Inc.

5429 Lyndon B. Johnson Freeway

Suite 700

Dallas, TX 75240

and in the case of Employee, to the address shown for Employee on the signature page hereof, or to such other address as either party may later specify by at least ten (10) days advance written notice delivered to the other party in accordance herewith.

6.10    No Waiver. The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver of that provision, nor prevent that party thereafter from enforcing that provision of any other provision of this Agreement.

6.11    Legal Fees and Expenses. In the event of any disputes under this Agreement, each party shall be responsible for their own legal fees and expenses which it may incur in resolving such dispute, unless otherwise prohibited by applicable law or a court of competent jurisdiction.

6.12    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Company and Employee have executed this Agreement, effective as of the day and year first above written.

American CareSource Holdings, Inc.

By: /s/ Kenneth S. George

Kenneth S. George, Chairman of the Board

EMPLOYEE:

By: /s/ Matthew D. Thompson

Matthew D. Thompson

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statement No. 333-133100 on Form S-3 and Nos. 333-133108, 333-143782, 333-159399 and 333-159400 on Form S-8 of American CareSource Holdings, Inc. of our report dated March 9, 2012 relating to our audit of the consolidated financial statements which appear in this Annual Report on Form 10-K of American CareSource Holdings, Inc for the year ended December 31, 2011.

/s/ McGladrey & Pullen, LLP

Des Moines, Iowa

March 9, 2012

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a)/15d-14(a)

Under the Securities Exchange Act of 1934, As Amended

I, Kenneth S. George, Chief Executive Officer of American CareSource Holdings, Inc., certify that:

1. I have reviewed this Annual Report on Form 10-K of American CareSource Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated divisions, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation, and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's first quarter in the case of this quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Dated:	March 9, 2012	By: /s/ Kenneth S. George
		Kenneth S. George
		Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a)/15d-14(a)

Under the Securities Exchange Act of 1934, As Amended

I, Matthew D. Thompson, Chief Financial Officer of American CareSource Holdings, Inc., certify that:

1. I have reviewed this Annual Report on Form 10-K of American CareSource Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated divisions, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation, and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's first quarter in the case of this quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Dated:	March 9, 2012	By: /s/ Matthew D. Thompson
		Matthew D. Thompson
		Chief Financial Officer

EX-32.1

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350,

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Kenneth S. George, Chief Executive Officer of American CareSource Holdings, Inc. (the “Company”), and Matthew D. Thompson, Chief Financial Officer of the Company, each certify pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. The Annual Report on Form 10-K of the Company for the year ended December 31, 2011, as filed with the Securities and Exchange Commission (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:	March 9, 2012	By: /s/ Kenneth S. George
		Kenneth S. George
		Chief Executive Officer
Dated:	March 9, 2012	By: /s/ Matthew D. Thompson
		Matthew D. Thompson
		Chief Financial Officer

This certification is made solely for the purpose of 18 U.S.C Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.

A signed original of this written statement required by Section 906 has been provided to American CareSource Holdings, Inc. and will be retained by American CareSource Holdings, Inc. and furnished to the Securities and Exchange Commission upon request.

XML

Allowance for Uncollectable Receivables and Refunds

12 Months Ended

Dec. 31, 2011

Allowance for Uncollectable Receivables [Abstract]

Allowance for Uncollectable Receivables and Refunds

Allowance for Uncollectable Receivables and Refunds

The Company maintains an allowance for uncollectable receivables which primarily relates to payor refunds.  Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. In some instances, we will recoup payment made to the ancillary service provider if the claim has been fully resolved. Co-payments, deductibles and co-insurance payments can also impact the collectability of claims.  While the Company is able to process a claim and estimate the cash it will receive from the payor for that claim, the presence of co-pays, deductibles and co-insurance payments can affect the ultimate collectability of the claim.  The Company records an allowance against revenue to better estimate collectability.   Provisions for refunds recorded, net against revenue, were approximately $622,000 and $695,000 for the years ended December 31, 2011 and 2010, respectively. The allowance was approximately $237,000 and $363,000 for the years ended December 31, 2011 and 2010, respectively.

XML

Concentration of Credit Risk

12 Months Ended

Dec. 31, 2011

Concentration of Credit Risk [Abstract]

Concentration of Credit Risk

Concentration of Credit Risk

The Company has two client payor relationships that individually comprise a significant portion of our net revenue.  The following is a summary of the approximate amounts of the Company’s net revenue and accounts receivable contributed by each of these clients as of and for the years ended December 31:

	2011								2010
	Accounts Receivable			Revenue			% of Total Revenue		Accounts Receivable			Revenue			% of Total Revenue
Client A	$	1,689		$	16,584		34	%	$	2,448		$	29,587		48	%
Client B	853			9,959			20		1,399			16,715			27
All other legacy clients	1,103			10,101			21		716			9,695			16
Clients implemented in 2010	854			11,901			24		1,310			5,899			10
Clients implemented in 2011	55			983			2		—			—			nm
Allowance for Uncollectable Receivables/Provision for Refunds	(237		)	(622		)	(1	)	(363		)	(695		)	(1	)
	$	4,317		$	48,906		100	%	$	5,510		$	61,201		100	%

Client A includes five entities and Client B includes two entities, which are aggregated for this presentation.

XML

Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Net revenues	$ 48,906	$ 61,201
Cost of revenues
Provider payments	37,588	45,789
Administrative fees	2,395	3,317
Claims administration and provider development	4,162	4,645
Total cost of revenues	44,145	53,751
Contribution margin	4,761	7,450
Selling, general and administrative expenses	6,240	6,190
Depreciation and amortization	792	767
Goodwill impairment charge	4,361	0
Total operating expenses	11,393	6,957
Operating income (loss)	(6,632)	493
Other income:
Other income	39	104
Income (loss) before income taxes	(6,593)	597
Income tax provision	644	111
Net income (loss)	$ (7,237)	$ 486
Earnings (loss) per common share:
Basic	$ (0.43)	$ 0.03
Diluted	$ (0.43)	$ 0.03
Basic weighted average common shares outstanding	17,005	16,550
Diluted weighted average common shares outstanding	17,005	17,176

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net income (loss)	$ (7,237)	$ 486
Adjustments to reconcile net income (loss) to net cash provided (used) by operations:
Stock-based compensation expense	738	871
Depreciation and amortization	792	767
Goodwill impairment charge	4,361	0
Unrealized gain on warrant derivative	0	(18)
Amortization of long-term client agreement	250	250
Client administration fee expense related to warrants	67	200
Deferred income taxes	614	47
Changes in operating assets and liabilities:
Accounts receivable	1,193	1,845
Prepaid expenses and other assets	(21)	157
Accounts payable and accrued liabilities	(188)	(432)
Due to service providers	(3,040)	(984)
Net cash provided by (used in) operating activities	(2,471)	3,189
Cash flows from investing activities:
Investment in software development costs	(611)	(402)
Additions to property and equipment	(58)	(300)
Net cash (used in) investing activities	(669)	(702)
Cash flows from financing activities:
Proceeds from exercise of equity warrants	0	157
Payment of income tax withholdings on net exercise of equity incentives	(57)	0
Net cash provided by (used in) financing activities	(57)	157
Net increase (decrease) in cash and cash equivalents	(3,197)	2,644
Cash and cash equivalents at beginning of period	14,512	11,868
Cash and cash equivalents at end of period	11,315	14,512
Supplemental cash flow information:
Cash paid for taxes, net of refunds received	52	103
Supplemental non-cash financing activity:
Income tax withholdings on exercise of equity incentives	$ 0	$ 19

XML

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

American CareSource Holdings, Inc. (“ACS,” “Company,”  the “Registrant,” “we,” “us,” or “our”) is an ancillary services company that offers cost effective access to a comprehensive national network of ancillary healthcare service providers.  The Company sells its services to a number of healthcare companies including preferred provider organizations ("PPOs"), third party administrators (“TPAs”), insurance companies, large self-funded organizations and various employee groups.  The Company offers payors this solution by:

• lowering its payors’ ancillary care costs throughout our network of high quality, cost effective providers that the Company has under contract at more favorable terms than they could generally obtain on their own; generally we provide our payor clients with 8-12% incremental savings on their ancillary healthcare services expenditures;

• providing payors with a comprehensive network of ancillary healthcare services providers that is tailored to each payor’s specific needs and is available to each payor’s covered persons for covered services;

• providing payors with claims management, reporting and processing and payment services;

• performing network/needs analysis to assess the benefits to payors of adding additional/different service providers to the payor -specific provider networks; and

• credentialing network service providers for inclusion in the payor -specific provider networks.  

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its one wholly-owned subsidiary, Ancillary Care Services, Inc.  All material intercompany accounts and transactions are eliminated in consolidation.  

Cash and Cash Equivalents

The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents include amounts in deposit accounts in excess of federally insured limits of $250,000.  The Company has not experienced any losses in such accounts.

Revenue Recognition

The Company recognizes revenue on the services that it provides, which includes (i) providing payor clients with a comprehensive network of ancillary healthcare providers, (ii) providing claims management, reporting, processing and payment services, (iii) providing network/need analysis to assess the benefits to payor clients of adding additional/different service providers to the client-specific provider networks and (iv) providing credentialing of network services providers for inclusion in the client payor-specific provider networks.  Revenue is recognized when services are delivered, which occurs after processed claims are billed to the client payors and collections are reasonably assured.  The Company estimates revenues and costs of revenues using average historical collection rates and average historical margins earned on claims.  Periodically, revenues are adjusted to reflect actual cash collections so that revenues recognized accurately reflect cash collected.

The Company determines whether it is acting as a principal or agent in the fulfillment of the services rendered.  After careful evaluation of the key gross and net revenue recognition indicators, the Company acknowledges that while the determination of gross versus net reporting is highly judgmental in nature, the Company has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

Following are the key indicators that support the Company’s conclusion that it acts as a principal when settling claims for service providers through its contracted service provider network:

• The Company is the primary obligor in the arrangement.  The Company has assessed its role as primary obligor as a strong indicator of gross reporting.  The Company believes that it is the primary obligor in its transactions because it is responsible for providing the services desired by its client payors.  The Company has distinct, separately negotiated contractual relationships with its client payors and with the ancillary health care providers in its networks.  The Company does not negotiate “on behalf of” its client payors and does not hold itself out as the agent of the client payors when negotiating the terms of the Company’s ancillary healthcare service provider agreements.  The Company’s agreements contractually prohibit client payors and service providers to enter into direct contractual relationships with one another.  The client payors have no control over the terms of the Company’s agreements with the service providers.  In executing transactions, the Company assumes key performance-related risks.  The client payors hold the Company responsible for fulfillment, as the provider, of all of the services the client payors are entitled to under their contracts; client payors do not look to the service providers for fulfillment.  In addition, the Company bears the pricing/margin risk as the principal in the transactions.  Because the contracts with the client payors and service providers are separately negotiated, the Company has complete discretion in negotiating both the prices it charges its client payors and the financial terms of its agreements with the service providers.  Since the Company’s profit is the spread between the amounts received from the client payors and the amount paid to the service providers, it bears significant pricing/margin risk.  There is no guaranteed mark-up payable to the Company on the amount the Company has contracted.  Thus, the Company bears the risk that amounts paid to the service provider will be greater than the amounts received from the client payors, resulting in a loss or negative claim.

• The Company has latitude in establishing pricing.  As stated above, the Company has complete latitude in negotiating the price to be paid to the Company by each client payor and the price to be paid to each contracted service provider.  This type of pricing latitude indicates that the Company has the risks and rewards normally attributed to a principal in the transactions.

• The Company changes the product or performs part of the services.  The Company provides the benefits associated with the relationships it builds with the client payors and the services providers.  While the parties could deal with each other directly, the client payors would not have the benefit of the Company’s experience and expertise in assembling a comprehensive network of service providers, in claims management, reporting and processing and payment services, in performing network/needs analysis to assess the benefits to client payors of adding additional/different service providers to the client payor-specific provider networks, and in credentialing network service providers.

• The Company has discretion in supplier selection.  The Company has complete discretion in supplier selection.  One of the key factors considered by client payors who engage the Company is to have the Company undertake the responsibility for identifying, qualifying, contracting with and managing the relationships with the ancillary healthcare service providers.  As part of the contractual arrangement between the Company and its client payors, the payors identify their obligations to their respective covered persons and then work with the Company to determine the types of ancillary healthcare services required in order for the payors to meet their obligations.  The Company may select the providers and contract with them to provide services at its discretion.

• The Company is involved in the determination of product or service specifications.  The Company works with its client payors to determine the types of ancillary healthcare services required in order for the payors to meet their obligations to their respective covered persons.  In some respects, the Company is customizing the product through its efforts and ability to assemble a comprehensive network of providers for its payors that is tailored to each payor’s specific needs.  In addition, as part of its claims processing and payment services, the Company works with the client payors, on the one hand, and the providers, on the other, to set claims review, management and payment specifications.

• The supplier (and not the Company) has credit risk.  The Company believes it has some level of credit risk, but that risk is mitigated because the Company does not remit payment to providers unless and until it has received payment from the relevant client payors following the Company’s processing of a claim.

• The amount that the Company earns is not fixed.  The Company does not earn a fixed amount per transaction nor does it realize a per-person per-month charge for its services.

The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company has general inventory risk.  The Company does not have any general inventory risk, as its business is not related to the manufacture, purchase or delivery of goods and it does not purchase in advance any of the services to be provided by the ancillary healthcare service providers.  While the absence of this risk would be one indicator in support of net revenue reporting, as described in detail above, the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that its circumstances are most consistent with those key indicators that support gross revenue reporting.

If the Company were to report its revenues net of provider payments rather than on a gross reporting basis, for the years ended December 31, 2011 and December 31, 2010, its net revenues would have been $11.3 million and $15.4 million, respectively.

The Company records a provision for refunds based on an estimate of historical refund amounts. Refunds are paid to payors for overpayments on claims, claims paid in error, and claims paid for non-covered services. In some instances, we will recoup payments made to the ancillary service provider if the claim has been fully resolved. The evaluation is performed periodically and is based on historical data. We present revenue net of the provision for refunds on the consolidated statement of operations.

Provider Payments

Payments to providers is the largest component of our cost of revenues and it consists of our payments for ancillary care services in accordance with contracts negotiated separately with providers for specific ancillary services.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual amounts could differ from those estimates.

Property and Equipment

Property and equipment are recorded at original cost and increased by the cost of any significant improvements subsequent to purchase.  The Company expenses repairs and maintenance as incurred.  Depreciation and amortization is calculated using the straight-line method over the shorter of the asset’s estimated useful life or the term of the lease in the case of leasehold improvements.  The Company capitalizes costs associated with software developed for internal use.  During 2011 and 2010, we capitalized approximately $611,000 and $402,000 of internally developed software costs, respectively.  

Research and Development

Research and development costs are expensed as incurred.

Income Taxes

Income taxes are accounted for under the asset and liability method.  Deferred taxes arise because of different treatment between financial statement accounting and tax accounting, known as “temporary differences”.  The Company records the tax effect of these temporary differences as “deferred tax assets” (generally items that can be used as a tax deduction or credit in the future periods) and “deferred tax liabilities” (generally items that we received a tax deduction for, which have not yet been recorded in the statement of operations).  The deferred tax assets and liabilities are measured using enacted tax rules and laws that are expected to be in effect when the temporary differences are expected to be recovered or settled.  A valuation allowance is established to reduce deferred tax assets considered to be more likely than not that the deferred tax assets will not be realized.

Stock Compensation

The Company records all stock-based payments to employees in the consolidated financial statements based on their estimated fair values as of the measurement date of the respective awards.  Additional information about the Company’s stock-based payment plan is presented in Note 8.

Segment and Related Information

The Company uses the “management approach” for reporting information about segments in our annual and interim financial statements.  The management approach is based on the way the chief operating decision-maker organizes segments within a company for making operating decisions and assessing performance.  Reportable segments are based on products and services, geography, legal structure, management structure and any other manner in which management disaggregates a company.  Based on the “management approach” model, the Company determined that our business is comprised of a single operating segment.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.  The fair value of instruments is determined by reference to various market data and other valuation techniques, as appropriate.  Unless otherwise disclosed, the fair value of short-term financial instruments approximates their recorded values due to the short-term nature of the instruments.

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 11,315	$ 14,512
Accounts receivable, net	4,317	5,510
Prepaid expenses and other current assets	559	532
Deferred income taxes	6	237
Total current assets	16,197	20,791
Property and equipment, net	1,829	1,824
Other assets:
Deferred income taxes	226	609
Other assets	16	340
Intangible assets, net	896	1,025
Goodwill	0	4,361
Total Assets	19,164	28,950
Current liabilities:
Due to service providers	3,678	6,718
Accounts payable and accrued liabilities	1,237	1,446
Total current liabilities	4,915	8,164
Commitments and contingencies
Shareholders' equity:
Preferred stock, $0.01 par value; 10,000 shares authorized, none issued	0	0
Common stock, $0.01 par value; 40,000 shares authorized; 17,076 and 16,922 shares issued and outstanding in 2011 and 2010, respectively	171	169
Additional paid-in capital	22,300	21,602
Accumulated deficit	(8,222)	(985)
Total shareholders' equity	14,249	20,786
Total Liabilities and Shareholder's Equity	$ 19,164	$ 28,950

XML

Significant Agreements

12 Months Ended

Dec. 31, 2011

Significant Client Agreements [Abstract]

Significant Agreements

Significant Agreements

During the year ended December 31, 2010, an ancillary service provider terminated its agreement with the Company to provide laboratory services in Texas to clients of the Company on an “as needed” basis.  Services provided by the provider accounted for approximately 3% of the Company’s net revenues in 2010.

The Company's second largest client continues to transition its payors and employer groups to alternative network options as a result of a business combination. While the Company has an enforceable contract in effect through May 2012, the client continues its transition, negatively impacting the claims volume and revenue generated from the account. The Company anticipates the transition will continue throughout 2012 and will be complete by December 31, 2012.

XML

Document and Entity Information (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Mar. 05, 2012	Jun. 30, 2011
Entity Information [Line Items]
Entity Registrant Name	American CareSource Holdings, Inc.
Entity Central Index Key	0001316645
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		17,075,620
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 12,442,784

XML

Employee Benefit Plans

12 Months Ended

Dec. 31, 2011

Employee Benefit Plans [Abstract]

Employee Benefit Plans

Employee Benefit Plans

The Company provides a defined contribution plan for employees meeting minimum service requirements.  Employees can contribute up to 100% of their current compensation to the plan subject to certain statutory limitations.  The Company contributes up to a maximum of 3.5% of an employee’s compensation and plan participants are fully-vested in the Company’s contributions immediately.  The Company made contributions to the plan and charged operations approximately $120,000 and $123,000 during the years ended December 31, 2011 and 2010, respectively.

XML

Consolidated Balance Sheets Parenthetical (USD $) In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Shareholders' equity:
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	40,000	40,000
Common stock, shares issued	17,076	16,922
Common stock, shares outstanding	17,076	16,922

XML

Goodwill Impairment and Intangible Assets

12 Months Ended

Dec. 31, 2011

Goodwill and Intangible Assets [Abstract]

Goodwill Impairment and Intangible Assets

Goodwill Impairment and Intangible Assets

Goodwill

The Company initiated an interim goodwill impairment analysis as of September 30, 2011. The Company concluded that impairment indicators existed based upon, among other things, the decline in market capitalization, revenue declines of the Company's two most significant client accounts and operating results for the nine months ended September 30, 2011, which required the performance of an interim impairment test. As a result, the Company performed the generally recognized threshold goodwill impairment test (step 1) which indicated that the fair value of the Company (single reporting unit), based primarily on the trading value of the Company's common stock plus an estimated control premium, was less than the book value of its net assets. Therefore, the required next analysis of the assessment was performed (step 2), in which the implied fair value of the Company's goodwill was compared to the book value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination, that is, the estimated fair value of the Company is allocated to all of those assets and liabilities (including both recognized and unrecognized intangible assets) as if the Company had been acquired in a business combination and the estimated fair value was the purchase price paid. If the carrying amount of goodwill is greater than the implied fair value of goodwill, an impairment loss is recognized in the amount of the excess and is charged to operations.

As a result of our preliminary interim impairment assessment, the Company recognized a non-cash goodwill impairment charge of $4.4 million as of September 30, 2011, representing the entire balance of goodwill. The Company subsequently finalized its analysis with no change to the preliminary results. In addition, the Company also reviewed the carrying value of intangible assets, which is limited to our ancillary provider network and property and equipment, to determine if impairment exists. Based on this analysis, the Company concluded that no impairment of the ancillary provider network or property and equipment existed as of September 30, 2011. A deferred tax benefit of $1.5 million was recognized as of September 30, 2011 as a result of the total amount of estimated impairment charges, but a valuation allowance was immediately provided.

The impairment was indicated as a result of the decline in the Company's stock price which the Company believes was caused by the continued declines in revenue and claims volume from the Company's two most significant clients and the expectation of significantly diminishing revenue from at least one of these clients. The impairment did not impact cash flows.

Intangibles

The ancillary provider network is being amortized using the straight-line method over their expected useful lives of 15 years.  Experience to date is that approximately 2-5% annual turnover or attrition of provider contracts occurs each year.  The ancillary provider network is being accounted for on a pooled basis and the actual cancellation rates of provider contracts that were acquired are monitored for potential impairment or amortization adjustment, if warranted.  As of December 31, 2011 and 2010, there were no indicators of impairment of the intangible assets.  The cost of adding additional providers is considered an ongoing operating expense.    

The following is a summary of our intangible assets as of December 31 for the years presented: 

	2011			2010
Ancillary provider network	$	1,921		$	1,921
Software	428			428
	2,349			2,349
Accumulated amortization	(1,453		)	(1,324		)
Intangibles, net	$	896		$	1,025

The capitalized value of the ancillary provider network that was acquired in the 2003 acquisition of the assets of our predecessor, American CareSource Corporation by Patient Infosystems (now CareGuide, Inc.), our former parent corporation. Amortization expense was approximately $128,000 for each of the years ended December 31, 2011 and 2010.  Amortization expense is estimated at $128,000 per year through 2018.

XML

Income Taxes

12 Months Ended

Dec. 31, 2011

Income Taxes [Abstract]

Income Taxes

Income Taxes

Income tax provision for the years ended December 31 differed from the U.S. federal income tax rate of 34% approximately in the amounts indicated as a result of the following:

	2011			2010
Computed “expected” tax provision	$	(2,242	)	$	203
Increase in the valuation allowance for deferred tax assets	2,752			—
State taxes	25			54
Short-fall on stock options and RSUs	145			—
Change in fair value of warrant derivative liability	—			(6		)
Return to provision adjustment	—			(167		)
Other	(36		)	27
Total income tax provision	$	644		$	111

Differences between financial accounting principles and tax laws cause differences between the bases of certain assets and liabilities for financial reporting purposes and tax purposes.

The tax effects of these differences, to the extent they are temporary, are recorded as deferred tax assets and liabilities and consisted of the following components:

	2011			2010
Deferred tax assets:
Operating loss carryforward	$	872		$	101
Accounts receivable allowance	72			69
Warrants	202			179
Texas tax credit carryforward	232			238
Stock option compensation	1,206			1,140
Goodwill	843			—
Accrued expenses	195			203
Alternative Minimum Tax credit carryforwards	16			16
Total deferred tax assets	3,638			1,946
Deferred tax liabilities:
Goodwill	—			(563		)
Property and equipment	(570		)	(496		)
Prepaid expense	(84		)	(41		)
Total deferred tax liabilities	(654		)	(1,100		)
Valuation allowance	(2,752		)	—
Net deferred tax assets	$	232		$	846

During the year ended December 31, 2011, the Company recognized a valuation allowance of approximately $2.8 million, which was included in the income tax provision for the year ended December 31, 2011. Due to the nature and timing of the reversal of the deferred tax assets and liabilities, the valuation allowance was established against the net deferred tax assets with the exception of the Texas tax credit carryforward of approximately $232,000.

As of December 31, 2011 and 2010, the net operating loss carryforwards were approximately $7.9 million and $5.7 million, which expire in 2025 through 2031. Included in the net operating loss carryforward is approximately $5.4 million which related to the excess tax benefits for stock options and warrants exercised which will result in a credit to additional paid in capital of approximately $1.9 million when the associated tax deduction results in a reduction in the income taxes payable.

The income tax provision shown on the statement of operations for the years ended December 31, 2011 and 2010 consisted of the following:

	2011		2010
Current	$	30	$	64
Deferred	614		47
	$	644	$	111

The Company has evaluated the accounting guidance for uncertainty in income taxes. Management has evaluated their material tax positions and determined no income tax effects with respect to the financial statements. The Company has identified the United States and Texas as major tax jurisdictions and is no longer subject to federal or state income tax examinations by tax authorities for years before 2007. The Company is currently undergoing an examination by tax authorities for its U.S. federal return for the year ended 2009.

XML

Quarterly Financial Information (unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information [Abstract]

Quarterly Financial Information (unaudited)

Quarterly Financial Information (unaudited)

The following table contains selected financial information from unaudited statements of operations for each quarter of 2011 and 2010.

	Quarters Ended
	2011											2010
	Dec. 31		Sept. 30			June 30			Mar. 31			Dec. 31		Sept. 30		June 30		Mar. 31
Net revenues	$	13,025	$	11,496		$	11,308		$	13,077		$	16,109	$	14,763	$	15,958	$	14,371
Contribution margin	1,647		781			844			1,489			1,678		1,706		2,098		1,968
Contribution margin %	12.6		6.8			7.5			11.4			10.4		11.6		13.1		13.7
Income (loss) before income taxes	150		(5,554		)	(965		)	(224		)	33		87		450		27
Net income (loss)	153		(6,523		)	(645		)	(222		)	142		44		299		1
Earnings (loss) per diluted share	0.01		(0.38		)	(0.04		)	(0.01		)	0.01		0.00		0.02		0.00
Shares used in computing diluted earnings (loss) per share	17,149		17,011			16,962			16,962			17,193		17,124		17,120		16,203

XML

Stock Warrants

12 Months Ended

Dec. 31, 2011

Stock Warrants [Abstract]

Stock Warrants

Stock Warrants

On July 2, 2007, the Company announced that it had signed an Ancillary Care Services Network Access Agreement (the “Ancillary Care Services Agreement”) effective as of May 21, 2007 (the “Effective Date”) with a new client, Texas True Choice, Inc. (“Texas True Choice”), a Texas-based preferred provider organization network, and certain subsidiaries of Texas True Choice. As partial compensation to Texas True Choice under the Ancillary Care Services Agreement, the Company issued to Corporate Health Plans of America, Inc., an affiliate of Texas True Choice, warrants to purchase a total of 225,000 shares of the Company’s common stock at an exercise price of $1.84, the closing price of the common stock of the Company as reported on the American Stock Exchange on the Effective Date. The Company valued the warrants when various measurement dates had been reached under the agreement.  Utilizing the Black-Scholes Merton valuation method, 112,500 warrants were valued at $0.94 in 2007, 56,250 warrants were valued at $2.87 at June 2008 and the remaining 56,250 were valued at $5.53 in June 2009.

These warrants vested 25% on the Effective Date, an additional 25% on each anniversary date of the Effective Date, and have an expiration date of May 20, 2012. As of December 31, 2010, all warrants to purchase shares of the Company's common stock were fully vested. The Company recorded the value of warrants as deferred costs upon vesting and amortized the deferred costs as administrative fees over the related contract term. As of December 31, 2010, the total unrecognized cost related to the warrants of approximately $67,000 was included as Prepaid and Other Current Assets and recognized as an expense through the term of the contract which expired in June 2011.  The weighted average remaining contractual life of the warrants is 0.8 years.

The Company entered into an agreement as of February 25, 2011 with an employee, whereby the Company agreed to issue warrants to purchase 250,000 shares of common stock with an exercise price of $1.67. The warrants vest in increments pursuant to the achievement of defined, agreed upon revenue targets generated by new clients within a five year term. The agreement also obligates the Company to issue warrants to purchase up to an additional 500,000 shares of common stock (issued in 250,000 increments) pursuant to the achievement of additional defined agreed upon revenue targets. During the twelve months ended December 31, 2011, we did not recognize compensation costs associated with these warrants due to the probability of vesting. That probability will be re-evaluated and updated based on current market conditions, on a quarterly basis, and compensation costs will be adjusted accordingly.

On February 1, 2012, certain terms of the agreement were modified, including the revenue targets and the total number of shares under the initial and future warrants. The warrant issuance now allows for 133,334 shares to be purchased at an exercise price of $0.50, 66,667 of which are vested, and the remaining 66,667 shares vesting upon the achievement of certain revenue targets. The number of shares under the future warrant issuances was also reduced to 266,666 (issued in 133,333 increments) shares based upon the achievement of additional defined agreed upon revenue targets.

A summary of stock warrant activity is as follows:

	Outstanding Warrants (thousands)		Weighted-Average Exercise Price
Outstanding at December 31, 2009	1,827		$	0.89
Exercised	(1,502	)	$	0.44
Outstanding at December 31, 2010	325		$	2.96
Granted	250		$	1.67
Cancelled	(100	)	$	5.51
Outstanding at December 31, 2011	475		$	1.75
Vested at December 31, 2011	225		$	1.84

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Commitments and Contingencies

The Company leases office space under a non-cancelable lease agreement, which expires in March 2013. In late 2011, the Company amended this agreement thereby partially terminating vacant space and reducing rent expense. Additionally the Company leases certain equipment under non-cancelable lease agreements, which expire at various dates through October 2014.

At December 31, 2011 minimum annual lease payments for operating leases are approximately as follows:

	Operating Leases
2012	$	380
2013	108
2014	14
Total minimum lease payments	$	502

Expense related to operating leases was approximately $347,000 and $363,000 for the years ended December 31, 2011 and 2010, respectively.

XML

Stock-Based Compensation

12 Months Ended

Dec. 31, 2011

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Stock-Based Compensation

Stock Options

American CareSource Holdings, Inc. has an Employee Stock Option Plan (the “Stock Option Plan”) for the benefit of certain employees, non-employee directors, and key advisors.  On May 16, 2005, the stockholders approved the 2005 Stock Option Plan which (i) authorized options to purchase 2,249,329 shares and (ii) established the class of eligible participants to include employees, nominees to the Board of Directors of American CareSource Holdings and consultants engaged by American CareSource Holdings, limited to 50,000 shares of Common Stock underlying the one-time grant of a Non-Qualified Option to which non-employee directors or non-employee nominees of the Board of Directors may be entitled.  Stock options granted under the Stock Option Plan may be of two types:  (1) incentive stock options and (2) nonqualified stock options.  The option price of such grants shall be determined by a Committee of the Board of Directors (the “Committee”), but shall not be less than the estimated fair value of the common stock at the date the option is granted.  The Committee shall fix the terms of the grants with no option term lasting longer than ten years.  The ability to exercise such options shall be determined by the Committee when the options are granted.

Over time this plan has been amended to increase the number of shares available to a total of 3,749,329 shares.

On May 19, 2009, the stockholders of the Company approved the 2009 Equity Incentive Plan (the “2009 Plan”).  The purpose of the 2009 Plan is (a) to allow selected employees and officers of the Company to acquire and increase equity ownership in the Company, which will strengthen their commitment to the success of the Company, and to attract new employees, officers and consultants, (b) to provide annual cash incentive compensation opportunities that are competitive with other peer corporations, (c) to optimize the profitability and growth of the Company through incentives that are consistent with the Company’s goals, (d) to provide grantees an incentive for individual excellence, (e) to promote teamwork and (f) to attract and retain highly-qualified persons to serve as non-employee directors.  The 2009 Plan allows for awards of non-qualified options, stock appreciation rights, restricted shares, performance units/shares, deferred stock, dividend equivalents and other stock-based awards up to 1,500,000 shares.  The term of the 2009 Plan is ten years and all non-qualified options will be valued at not less than 100% of the market value of the Company’s stock on the date of grant.

Shares of common stock reserved for future grants under the Stock Option Plan and the 2009 Plan (the “Plans”) were 1,640,869 and 1,502,813 at December 31, 2011 and 2010, respectively.

Compensation expense related to all equity awards, including non-qualified stock options and restricted stock units, that has been charged against income for the years ended December 31, 2011 and 2010 was approximately $738,000 and $871,000, respectively.

The awards granted to employees and non-employee directors become exercisable over periods of up to five years.  The fair value of each option award granted is estimated on the date of grant using the Black-Scholes-Merton valuation model that uses the assumptions noted in the following table.  Volatility is calculated using an analysis of historical volatility.  The Company believes that the historical volatility of the Company’s stock is the best method for estimating future volatility.  The expected lives of options are determined based on the Company’s historical share option exercise experience.  The Company believes the historical experience method is the best estimate of future exercise patterns currently available.  The risk-free interest rates are determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the options.  The expected dividend yields are based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant. 

	2011			2010
Weighted average grant date fair value	$	0.63		$	1.04
Weighted average assumptions used
Expected volatility	66.9		%	69.3		%
Expected lives (years)	6.1			6.3
Risk free interest rate	1.6		%	2.6		%
Forfeiture rate	20.5		%	20.5		%
Dividend rate	—			—

A summary of stock option activity is as follows:

	Options (thousands)		Weighted-Average Exercise Price
Outstanding at December 31, 2009	2,488		$	3.52
Granted	964		$	1.70
Forfeited	(479	)	$	5.25
Cancelled	(374	)	$	5.47
Outstanding at December 31, 2010	2,599		$	2.24
Granted	280		$	1.03
Forfeited	(165	)	$	2.11
Cancelled	(235	)	$	2.94
Exercised	(261	)	$	0.37
Outstanding at December 31, 2011	2,218		$	2.24
Exercisable at December 31, 2011	1,318		$	2.45

As of December 31, 2011, the weighted average remaining contractual life of the options outstanding was 7.1 years and the weighted average remaining contractual life of the outstanding exercisable options was 6.1 years.

The following table summarizes information concerning outstanding and exercisable options at December 31, 2011:

(in thousands)	Options Outstanding				Options Exercisable
Range of Exercise Price	Number Outstanding	Weighted Average Outstanding Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
Under $1.00	349	6.4	$	0.50	229	$	0.41
$1.00 - $2.00	939	7.4	$	1.65	536	$	1.77
$2.01 - $3.00	519	7.6	$	2.23	224	$	2.45
$3.01 - $4.00	45	6.2	$	3.29	42	$	3.29
$4.01 - $5.00	208	6.4	$	4.17	169	$	4.18
$5.01 - $6.00	50	4.1	$	5.60	50	$	5.60
$6.01 - $7.00	7	6.9	$	7.00	5	$	7.00
Greater than $7.01	101	7.0	$	7.35	63	$	7.49

The total intrinsic value of options outstanding at December 31, 2011 and 2010 was approximately $21,000 and $465,000, respectively.  The total intrinsic value of the options that are exercisable at December 31, 2011 and 2010 was approximately $21,000 and $462,000, respectively. The total intrinsic value of options exercised during the year ended December 31, 2011 was approximately $127,000. No options were exercised during the year ended December 31, 2010.

Compensation expense related to non-qualified stock options charged to operations during 2011 was approximately $630,000. As of December 31, 2011, there was approximately $778,000 of total unrecognized compensation cost related to non-vested non-qualified stock options granted under the plan.  The cost is expected to be recognized over a weighted average period of 3.1 years.

Restricted Stock Units

Under the 2009 Plan, the Company issued restricted stock units (“RSUs”) to certain employees and the Board of Directors during the twelve months ended December 31, 2009.  As RSUs vest, they are convertible into shares of the Company’s common stock.  The RSUs are valued at the market price of the Company’s stock on the measurement date, which is the date of grant. Compensation expense is recognized ratably over the vesting period.  Our future estimated forfeiture rate on RSUs is 0% as the RSUs have been awarded primarily to members of our Board of Directors and members of senior management of the Company. No RSUs were issued during the twelve months ended December 31, 2011 and 2010.

A summary of RSU activity is as follows:

	RSUs		Weighted-Average Grant Date Fair Value
Outstanding at December 31, 2009	140		$	6.99
Forfeited	(23	)	$	6.68
Converted to common stock	(31	)	$	7.02
Outstanding at December 31, 2010	86		$	7.07
Forfeited	(18	)	$	1.86
Converted to common stock	(50	)	$	3.87
Outstanding at December 31, 2011	18		$	7.15
Vested and convertible to common stock at December 31, 2011	3		$	7.02

Compensation expense related to RSUs charged to operations during 2011 and 2010 was approximately $108,000 and $272,000, respectively. As of December 31, 2011, there was approximately $86,000 of total unrecognized compensation cost related to non-vested RSUs granted under the plan. The cost is expected to be recognized over a weighted average period of 2.3 years.

XML

Earnings (Loss) Per Share

12 Months Ended

Dec. 31, 2011

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (or loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings (loss) per share reflects the potential dilution that could occur if options, warrants and restricted stock units to purchase common stock were exercised or converted. For purposes of this calculation, outstanding stock options, stock warrants and restricted stock units are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding.  

For the year ended December 31, 2011, options to purchase approximately 2.0 million shares of commons stock, warrants to purchase approximately 475,000 shares of common stock, and approximately 15,000 unvested restricted stock units were excluded from the calculation as their impact would be anti-dilutive.

The following table details the reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share (amounts in thousands except per share amounts):

	2011			2010
Numerator:
Net income (loss) for basic earnings per share	$	(7,237	)	$	486
Less:
Change in fair value of warrant derivative liability	—			18
Net income for diluted earnings (loss) per share	$	(7,237	)	$	468
Denominator:
Weighted-average basic common shares outstanding	17,005			16,550
Assumed conversion of dilutive securities:
Stock options	—			271
Warrants	—			355
Restricted stock units	—			—
Potentially dilutive common shares	—			626
Denominator for diluted earnings (loss) per share – Adjusted weighted-average shares	17,005			17,176
Earnings (loss) per common share:
Basic	$	(0.43	)	$	0.03
Diluted	$	(0.43	)	$	0.03

XML

Consolidated Statement of Stockholders' Equity (USD $) In Thousands, unless otherwise specified	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2009	$ 19,290	$ 156	$ 20,605	$ (1,471)
Balance, shares at Dec. 31, 2009		15,642
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	486			486
Stock-based compensation expense	871		871
Issuance of common stock upon exercise of restricted stock units, net of tax withholdings, shares		23
Issuance of common stock upon conversion of restricted stock units, net of tax withholdings	(18)	1	(19)
Issuance of common stock upon exercise of stock warrants, shares		1,257
Issuance of common stock upon exercise of stock warrants	157	12	145	0
Balance at Dec. 31, 2010	20,786	169	21,602	(985)
Balance, shares at Dec. 31, 2010	16,922	16,922
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(7,237)			(7,237)
Stock-based compensation expense	738		738
Issuance of common stock upon exercise of restricted stock units, net of tax withholdings, shares		154
Issuance of common stock upon conversion of restricted stock units, net of tax withholdings	(38)	2	(40)	0
Balance at Dec. 31, 2011	$ 14,249	$ 171	$ 22,300	$ (8,222)
Balance, shares at Dec. 31, 2011	17,076	17,076

XML

Property and Equipment

12 Months Ended

Dec. 31, 2011

Property and Equipment [Abstract]

Property and Equipment

Property and Equipment

Property and equipment, net consists of the following:

	Useful Lives (years)	2011			2010
Software – internally developed	5	$	2,177		$	1,566
Software – purchased	3-5	592			576
Computer equipment	3-5	507			465
Furniture and fixtures	5	356			356
Leasehold improvements	7	205			205
		3,837			3,168
Accumulated depreciation and amortization		(2,008		)	(1,344		)
Property and equipment, net		$	1,829		$	1,824

The Company recognized depreciation expense of approximately $664,000 and $639,000 during 2011 and 2010, respectively. The depreciation amounts include approximately $330,000 and $260,000 of amortization of internally developed software during 2011 and 2010, respectively.

The Company capitalizes costs associated with internally developed software, developed for internal use only, during the application development stage. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. Costs of significant upgrades and enhancements that result in additional functionality also are capitalized, whereas costs incurred for maintenance and minor upgrades and enhancements are expensed as incurred. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose.

During the years ended December 31, 2011 and December 31, 2010, the Company capitalized costs related to enhancements to its internal information technology claims management applications. The applications were originally developed in 2005 and from time to time, the Company will enhance the functionality and reporting capabilities of the applications. The enhancements are typically developed by the Company's internal information technology group. Periodically, third-party consultants will be utilized to perform the development. For internal resources, the Company capitalizes salary and related benefits, while it capitalizes the cost of external consultants.